Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 1019-6439 Online ISSN: 1791-2423
Journal Cover
December-2026 Volume 69 Issue 6

Full Size Image

Cover Legend PDF

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
December-2026 Volume 69 Issue 6

Full Size Image

Cover Legend PDF

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Review Open Access

Metabolic‑epigenetic coupling via lysine lactylation drives cancer stemness and multidrug resistance (Review)

  • Authors:
    • Ying Yang
    • Nan Zhang
    • Dan Wang
    • Dongmei Ye
    • Yun Zhang
    • Xiaoju Li
  • View Affiliations / Copyright

    Affiliations: Department of Pathology, Honghui Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710054, P.R. China, Department of Pathology, The First Hospital of Nanchang City, Nanchang, Jiangxi 330000, P.R. China
    Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 142
    |
    Published online on: November 9, 2026
       https://doi.org/10.3892/ijo.2026.5955
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:


Abstract

Lysine lactylation couples glycolytic flux with epigenetic regulation, driving cancer stemness and therapeutic resistance. The Warburg effect generates L‑lactate, which through enzymatic (AARS1/2, HBO1, KAT8) and non‑enzymatic mechanisms deposits lactyl groups on histones and non‑histone proteins. This modification sustains cancer stem cell self‑renewal via histone mark deposition at stemness gene promoters and non‑histone modification of key regulators (SOX9 and β‑catenin). Concurrently, lactylation enhances DNA repair, suppresses ferroptosis and stabilizes stemness‑associated transcription factors, conferring resistance to chemotherapy, targeted agents and immunotherapy. Crosstalk with acetylation, ubiquitination and phosphorylation adds regulatory complexity. Preclinical targeting of lactate metabolism, lactyltransferases, or delactylases shows therapeutic promise, while lactylation‑based signatures may stratify patient responses. The present review synthesized current evidence establishing lactylation as a metabolic‑epigenetic node and summarized convergent resistance mechanisms that may inform future therapeutic strategies.

Introduction

Cancer stemness and drug resistance represent interconnected drivers of tumor progression, recurrence, and therapeutic failure. The persistence of cancer stem cells (CSCs) has been increasingly recognized as a fundamental barrier to durable treatment response across multiple malignancies. Duval et al (1) recently demonstrated that SRY-box transcription factor 9 (SOX9) drives a stem-like transcriptional state and platinum resistance in high-grade serous ovarian cancer, establishing that stemness regulators directly mediate chemoresistance. Hubert et al (2) further identified an epigenetic axis of stem cell maintenance and chemoresistance in colon cancer, highlighting how epigenetic programs sustain CSC populations despite chemotherapy exposure. These findings establish that stemness and drug resistance are intimately linked through epigenetic mechanisms, although the upstream metabolic signals that coordinate this relationship remain incompletely understood.

Metabolic reprogramming and epigenetic dysregulation constitute hallmarks of CSC maintenance and multidrug resistance. The Warburg effect generates substantial lactate accumulation that extends beyond its traditional role as a metabolic waste product. Li et al (3) revealed a positive feedback regulation between glycolysis and histone lactylation that drives oncogenesis in pancreatic ductal adenocarcinoma, providing direct evidence linking glycolytic flux to malignant progression. Yang et al (4) further demonstrated that histone lactylation-driven feedback loops modulate cholesterol-linked immunosuppression in pancreatic cancer, illustrating how metabolic-epigenetic circuits sustain tumor growth. Notably, lactate functions not merely as a metabolic intermediate but also a signaling molecule that coordinates the metabolic-epigenetic interface, although the precise molecular mechanisms bridging glycolysis to epigenetic regulation in CSCs require further elucidation.

Protein lysine lactylation (Kla) has emerged as a post-translational modification that directly couples the cellular metabolic state to epigenetic regulation. Yang et al (5) conducted a comprehensive lactylome analysis in hepatocellular carcinoma, revealing lactylation-dependent mechanisms of metabolic adaptation that enable cancer cells to thrive under nutrient stress. Liu et al (6) recently reported that nuclear GTP-specific succinyl-CoA synthetase (GTPSCS) functions as a lactyl-CoA synthetase to promote histone lactylation and gliomagenesis, establishing compartment-specific regulatory mechanisms. Sun et al (7) provided a conceptual framework linking the Warburg effect to DNA damage repair through lactylation, synthesizing how metabolic reprogramming directly affects genome stability and therapeutic response. A critical comparison across these studies reveals that lactylation exerts context-dependent effects on both chromatin dynamics and DNA repair pathways, suggesting that the functional consequences vary substantially across cancer types.

The convergence of lactylation with cancer stemness and drug resistance has recently emerged as a frontier in cancer biology. Feng et al (8) performed comprehensive lactylome analysis in liver CSCs, unveiling lactylation-dependent mechanisms of stemness remodeling and identifying pathways specifically activated in the CSC compartment compared with differentiated tumor cells. Lv et al (9) demonstrated that sirtuin 4 (SIRT4) promotes pancreatic cancer stemness by enhancing histone lactylation and epigenetic reprogramming stimulated by calcium signaling, highlighting the interplay between metabolic signals and stemness maintenance. Regarding drug resistance, Gan et al (10) established that a tumor-derived lactate/enolase 1 (ENO1) lactylation feedback loop facilitates osimertinib resistance in lung adenocarcinoma, demonstrating how lactylation creates self-reinforcing circuits that sustain therapeutic escape. Zhao et al (11) further reported a deubiquitination-lactylation circuit in gastric adenocarcinoma stemness, as detailed in the CSC stemness as a hub for lactylation-driven multidrug resistance section. Importantly, lactylation-driven stemness and drug resistance operate through convergent mechanisms including enhanced DNA repair capacity, suppression of cell death pathways, and activation of pluripotency-associated programs, although the relative contribution of each mechanism varies across cancer types and therapeutic contexts. The present review systematically synthesized current evidence establishing lactylation as a critical node linking metabolic reprogramming to cancer stemness and drug resistance, evaluated therapeutic opportunities and identified key unresolved questions in this rapidly evolving field.

Biochemical basis and regulatory machinery of protein lactylation

The biochemical foundation of lactylation rests on the stereospecific recognition of L-lactate as the primary substrate, with enzymatic systems including both alanyl-tRNA synthetase 1/2 (AARS1/2) and classical acetyltransferases [histone acetyltransferase binding to ORC1 (HBO1), lysine acetyltransferase 8 (KAT8), lysine acetyltransferase 2A (KAT2A)] catalyzing lactyl group deposition. Reversibility is conferred by delactylases such as histone deacetylases 1-3 (HDAC1-3), sirtuin 3 (SIRT3), and sirtuin 6 (SIRT6), while reader proteins including tripartite motif-containing protein 33 (TRIM33) and double PHD fingers 2 (DPF2) interpret lactylation marks to drive transcriptional programs. Subcellular compartmentalization, including nuclear, mitochondrial, and cytoplasmic distribution, adds regulatory specificity. Fig. 1 provides a comprehensive overview of the lactylation regulatory machinery, depicting writers, erasers, readers, and their subcellular distribution.

Regulatory machinery of protein
lactylation. L-lactate is converted to lactyl-CoA or directly used
by writers (AARS1/2, HBO1, KAT8, KAT2A, GTPSCS) to deposit lactyl
groups on histones and non-histone proteins. Erasers (HDAC1-3,
SIRT3, SIRT6) remove lactylation. Readers (TRIM33, DPF2, BRD9)
interpret Kla marks. The process occurs in nucleus, cytoplasm and
mitochondria, with crosstalk to other PTMs. AARS1/2, alanyl-tRNA
synthetase 1/2; HBO1, histone acetyltransferase binding to ORC1;
KAT8, lysine acetyltransferase 8; KAT2A, lysine acetyltransferase
2A; GTPSCS, GTP-specific succinyl-CoA synthetase; HDAC1-3, histone
deacetylases 1-3; SIRT3, sirtuin 3; SIRT6, sirtuin 6; TRIM33,
tripartite motif-containing protein 33; DPF2, double PHD fingers 2;
BRD9, bromodomain-containing protein 9; Kla, lysine lactylation;
PTM, post-translational modification.

Figure 1

Regulatory machinery of protein lactylation. L-lactate is converted to lactyl-CoA or directly used by writers (AARS1/2, HBO1, KAT8, KAT2A, GTPSCS) to deposit lactyl groups on histones and non-histone proteins. Erasers (HDAC1-3, SIRT3, SIRT6) remove lactylation. Readers (TRIM33, DPF2, BRD9) interpret Kla marks. The process occurs in nucleus, cytoplasm and mitochondria, with crosstalk to other PTMs. AARS1/2, alanyl-tRNA synthetase 1/2; HBO1, histone acetyltransferase binding to ORC1; KAT8, lysine acetyltransferase 8; KAT2A, lysine acetyltransferase 2A; GTPSCS, GTP-specific succinyl-CoA synthetase; HDAC1-3, histone deacetylases 1-3; SIRT3, sirtuin 3; SIRT6, sirtuin 6; TRIM33, tripartite motif-containing protein 33; DPF2, double PHD fingers 2; BRD9, bromodomain-containing protein 9; Kla, lysine lactylation; PTM, post-translational modification.

Chemical and enzymatic basis of lactylation

Lysine lactylation represents a covalent modification wherein a lactyl group is attached to the ε-amino group of lysine residues. The discovery by Zhang et al (12) first demonstrated that histone lactylation occurs in response to elevated lactate levels, establishing a direct connection between glycolytic metabolism and epigenetic control. Liberti and Locasale (13) subsequently highlighted that this modification serves as a metabolic sensor, enabling cells to translate glucose-derived lactate into chromatin-based transcriptional programs. From a stereochemical perspective, lactate exists as L-lactate and D-lactate enantiomers in biological systems. Recent work by Zhang et al (14) demonstrates that L-lactate is the predominant isoform driving lysine lactylation under glycolytic conditions, with quantitative proteomics revealing that over 90% of lactylation sites are modified by L-lactate. Moreno-Yruela et al (15) provided critical insights into the chiral specificity of this modification, emphasizing that stereoselective recognition by reader proteins determines downstream functional outcomes.

The enzymatic basis of lactylation has been substantially advanced through identification of writer and eraser machineries. Zong et al (16) and Ju et al (17) independently identified alanyl-tRNA synthetase AARS1 as a primary lactyltransferase that directly transfers lactate to lysine residues, demonstrating that AARS1 senses intracellular lactate and catalyzes global protein lactylation. Mechanistically, AARS1 binds lactate with high affinity and utilizes ATP to generate lactyl-AMP as an activated intermediate. Complementing these findings, Li et al (18) showed that both AARS1 and AARS2 function as universal lactyltransferases, with AARS2 localizing to mitochondria to regulate mitochondrial protein lactylation. In parallel, Liu et al (6) identified nuclear GTPSCS as a lactyl-CoA synthetase that generates lactyl-CoA specifically in the nucleus to promote histone lactylation, revealing compartment-specific lactylation regulatory mechanisms. Niu et al (19) demonstrated that HBO1 serves as a histone lactyltransferase catalyzing histone H3 lysine 9 lactylation (H3K9la), while Xie et al (20) showed KAT8 mediates eukaryotic translation elongation factor 1 alpha 2 (eEF1A2) lactylation in colorectal cancer. Zhu et al (21) further revealed that acyl-CoA synthetase short-chain family member 2 acts as a lactyl-CoA synthetase coupling with KAT2A to form a functional lactyltransferase complex. Collectively, these studies establish that multiple enzymatic systems, including both aminoacyl-tRNA synthetase-family enzymes and classical histone acetyltransferases, contribute to the mammalian lactylome. Notably, Zhang et al (22) provided evidence for non-enzymatic lysine lactylation under high-lactate conditions, suggesting both enzymatic and non-enzymatic mechanisms operate in cancer cells.

Delactylation machinery and reader proteins

The reversibility of lactylation is mediated by specific eraser enzymes. Moreno-Yruela et al (23) demonstrated that class I HDAC1-3 possess intrinsic delactylase activity, catalyzing removal of lactyl groups from histones. These findings were further supported by independent studies (24,25). Nickel et al (26) identified SIRT6 as a histone delactylase, expanding the repertoire of eraser enzymes to the sirtuin family. Chen et al (27) showed SIRT3 specifically removes H3K9la to suppress esophageal cancer progression, while Zou et al (28) demonstrated SIRT6-mediated H3K9 delactylation inhibits O6-methylguanine-DNA methyltransferase (MGMT) transcription to reverse temozolomide resistance. Jin et al (29) revealed SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth. He et al (30) reported that HDAC2-mediated methyltransferase-like 3 (METTL3) delactylation promotes DNA repair and chemotherapy resistance. These discoveries establish that multiple deacetylases exhibit delactylase activity, though substrate specificity and context-dependent regulation remain active areas of investigation.

Functional interpretation of lactylation marks requires reader proteins that recognize specific Kla sites. Nuñez et al (31) demonstrated that the TRIM33 bromodomain recognizes histone lactylation with selectivity distinct from acetylation recognition. Zhai et al (32) identified DPF2 as a histone lactylation reader that drives transcription and tumorigenesis. Wei et al (33) showed that BRD9 recognizes histone H3 lysine 18 lactylation (H3K18la) to drive oncogenic chromatin remodeling. The identification of specific readers remains incomplete, representing a critical gap in understanding lactylation-mediated signaling.

Subcellular compartmentalization and regulatory integration

Lactylation exhibits distinct subcellular distribution patterns in cancer cells. Bao et al (34) performed systematic subcellular proteomic mapping, revealing that lactylated proteins are predominantly enriched in the nucleus, mitochondria, and cytoplasm. He et al (35) demonstrated that Numb/Parkin-directed mitochondrial fitness governs histone lactylation via metabolic regulation, linking organellar homeostasis to nuclear epigenetic modifications. Mao et al (36) showed hypoxia induces mitochondrial protein lactylation to limit oxidative phosphorylation, establishing that mitochondrial lactylation directly impacts metabolic adaptation. The interplay between lactylation and other post-translational modification (PTM) adds regulatory complexity. Huang et al (37) revealed a general control non-derepressible 5 (GCN5)-extracellular signal-regulated kinase (ERK) lactylation-phosphorylation amplification loop that accelerates cancer progression. Sun et al (38) demonstrated crosstalk between HDAC6-catalyzed α-tubulin lactylation and acetylation in cytoskeleton regulation. Zhou et al (39) reported hypoxia-induced protein arginine methyltransferase 1 (PRMT1) lactylation drives vimentin arginine asymmetric dimethylation. These findings indicate that lactylation integrates with established PTM networks to fine-tune oncogenic signaling.

Lactylation is detected mainly by antibody-based methods, mass spectrometry-based proteomics, and genetic code expansion, each with distinct limitations. Pan-Kla antibodies are widely used but may cross-react with acetylation and other short-chain acylations because of structural similarity; site-specific antibodies require validation against competing acyl modifications and modification-deficient controls (14,15). Mass spectrometry enables unbiased site mapping but is limited by low lactylation stoichiometry, enrichment bias, isobaric interference, and the general inability to distinguish enzymatic from non-enzymatic deposition or L- from D-lactate without chiral resolution (22,34). Genetic code expansion allows site-specific incorporation of lactyl-lysine in living cells and can provide causal evidence, but remains technically demanding and limited in scale. Accordingly, the strongest mechanistic claims are those supported by orthogonal validation, ideally combining MS-based site identification with validated site-specific antibodies and functional rescue (22).

In summary, the biochemical machinery of lactylation encompasses diverse writers (AARS1, AARS2, HBO1, KAT8, KAT2A) and erasers (HDAC1-3, SIRT3, SIRT6) operating across subcellular compartments. Compared with acetylation, lactylation exhibits distinct stereospecificity, substrate preferences, and metabolic sensitivity. Notably, the relative contributions of enzymatic vs. non-enzymatic lactylation in cancer cells remain debated and systematic identification of lactylation readers represents an urgent priority for the field. However, writer and reader assignments often rely on overexpression, pan-Kla antibodies, or a limited set of bromodomain proteins, and chiral specificity is rarely resolved in cancer models (14,15,22,31,32,34). These limitations should be considered when interpreting the lactylation machinery.

Metabolic reprogramming drives the lactylation landscape in cancer

The Warburg effect establishes a metabolic foundation wherein aerobic glycolysis generates substantial lactate accumulation, creating a substrate reservoir for protein lactylation in malignant cells. Metabolic reprogramming shapes the cancer lactylation landscape through four interconnected mechanisms: lactate production as the biochemical corner-stone, oncogenic pathway regulation of lactylation dynamics, tumor microenvironment (TME) metabolic crosstalk, and spatial heterogeneity of lactylation patterns within tumor tissues (Fig. 2). Recent advances have substantially expanded understanding of how glycolytic flux translates into epigenetic marks, with emerging evidence implicating lactylation in cancer stemness and therapy resistance.

Metabolic reprogramming drives the
cancer lactylation landscape. There are four interconnected
mechanisms: Warburg effect and lactate accumulation; aerobic
glycolysis produces L-lactate, the substrate for lactylation,
oncogenic and hypoxic regulation; HIF1α, KRAS, BRAF and hypoxia
enhance glycolysis/lactate production, promoting
histone/non-histone lactylation; TME metabolic crosstalk; CAFs
provide lactate; lactate induces MOESIN, METTL3 and PD-L1
lactylation in immune cells, fostering immunosuppression; spatial
and single-cell heterogeneity; lactylation is enriched in CSCs and
varies across tumor regions, correlating with therapy resistance.
HIF1α, hypoxia-inducible factor 1α; KRAS, Kirsten rat
sarcoma viral oncogene homolog; BRAF, B-Raf proto-oncogene;
TME, tumor microenvironment; CAF, cancer-associated fibroblast;
MOESIN, membrane-organizing extension spike protein; METTL3,
methyltransferase-like 3; PD-L1, programmed death-ligand 1; CSC,
cancer stem cell; LDHA, lactate dehydrogenase A.

Figure 2

Metabolic reprogramming drives the cancer lactylation landscape. There are four interconnected mechanisms: Warburg effect and lactate accumulation; aerobic glycolysis produces L-lactate, the substrate for lactylation, oncogenic and hypoxic regulation; HIF1α, KRAS, BRAF and hypoxia enhance glycolysis/lactate production, promoting histone/non-histone lactylation; TME metabolic crosstalk; CAFs provide lactate; lactate induces MOESIN, METTL3 and PD-L1 lactylation in immune cells, fostering immunosuppression; spatial and single-cell heterogeneity; lactylation is enriched in CSCs and varies across tumor regions, correlating with therapy resistance. HIF1α, hypoxia-inducible factor 1α; KRAS, Kirsten rat sarcoma viral oncogene homolog; BRAF, B-Raf proto-oncogene; TME, tumor microenvironment; CAF, cancer-associated fibroblast; MOESIN, membrane-organizing extension spike protein; METTL3, methyltransferase-like 3; PD-L1, programmed death-ligand 1; CSC, cancer stem cell; LDHA, lactate dehydrogenase A.

The Warburg effect and lactate accumulation

The pioneering discovery by Zhang et al (12) demonstrated that histone lactylation directly responds to elevated lactate levels, establishing a mechanistic link between glycolytic metabolism and epigenetic control. Subsequent work confirmed that lactate modulates cellular metabolism through histone lactylation-mediated gene expression in non-small cell lung cancer, showing that exogenous lactate supplementation induces H3K18la and histone H4 lysine 12 lactylation (H4K12la) at concentrations corresponding to tumor microenvironmental levels (40). Lactate functions as an active signaling metabolite that orchestrates pro-tumor microenvironment during carcinogenesis (41). Gu et al (42) demonstrated that tumor metabolite lactate promotes tumorigenesis by modulating membrane-organizing extension spike protein (MOESIN) lactylation and enhancing transforming growth factor beta signaling in regulatory T cells, revealing that lactate functions beyond histone modifications to influence non-histone protein function.

Quantitative proteomic analyses have established the breadth of the lactylation landscape. Yang et al (43) identified hundreds of lysine-lactylated substrates in gastric cancer cells across diverse functional categories, establishing that lactylation is a widespread modification rather than restricted to histones. Global profiling in hepatocellular carcinoma by Hong et al (44) identified over 2,000 lactylation sites, with enrichment in proteins involved in metabolic processes and RNA splicing. Yang et al (5) performed comprehensive lactylome analysis in hepatocellular carcinoma, demonstrating lactylation-dependent mechanisms of metabolic adaptation. More recently, lactylation has been shown to stabilize transcription factor EB to elevate autophagy and lysosomal activity, linking lactate accumulation to organellar homeostasis (45). The quantitative relationship between glycolytic flux and lactylation intensity has been systematically examined through integrated multi-omics approaches (46,47). Collectively, these studies establish that the magnitude of the Warburg effect directly correlates with global lactylation levels, though non-enzymatic mechanisms may predominate under extreme metabolic stress conditions. However, most evidence is correlative because lactate supplementation, LDHA inhibition, or glycolytic blockade alters multiple metabolites and PTMs simultaneously; few studies rescue lactylation at defined sites.

Oncogenic and hypoxic regulation

Oncogenic signaling pathways profoundly shape the cancer lactylation signature through transcriptional and post-transcriptional control of glycolytic enzymes. Luo et al (48) demonstrated that hypoxia-inducible factor 1-alpha (HIF1α) lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer, revealing a feed-forward loop wherein HIF1α both responds to and drives lactylation. A positive feedback loop between inactive Von Hippel-Lindau tumor suppressor-triggered histone lactylation and platelet-derived growth factor receptor beta signaling drives clear cell renal cell carcinoma progression, establishing that tumor suppressor loss can initiate lactylation-dependent oncogenic cascades (49). The functional consequences of oncogene-driven lactylation were further elaborated by studies showing that BRAF V600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation (50), while Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation increases histone H3K9 lactylation to promote colorectal cancer progression (51).

Hypoxia represents a dominant physiological driver of lactylation. Recent work by Gao et al (52) performed dynamic investigation of hypoxia-induced L-lactylation, revealing time-dependent accumulation of lactylation marks under oxygen deprivation. Hypoxia induces mitochondrial protein lactylation to limit oxidative phosphorylation, establishing that mitochondrial lactylation directly impacts metabolic adaptation (36). Hypoxia also promotes H3K9 lactylation to enhance LAMC2 transcription in esophageal squamous cell carcinoma (53) and induces β-catenin lactylation to promote colorectal cancer cell proliferation and stemness via the wingless-related integration site (Wnt) signaling pathway (54). Zhou et al (39) reported that hypoxia-induced PRMT1 lactylation drives vimentin arginine asymmetric dimethylation in tumor metastasis, demonstrating crosstalk between lactylation and other post-translational modifications. A comparative analysis across studies reveals that hypoxia-induced lactylation preferentially targets chromatin-associated proteins, whereas normoxia-driven lactylation exhibits broader subcellular distribution. He et al (35) provided mechanistic integration by demonstrating that Numb/Parkin-directed mitochondrial fitness governs cancer cell fate via metabolic regulation of histone lactylation, showing that mitochondrial homeostasis determines the availability of lactate for nuclear epigenetic modifications.

Tumor microenvironment and metabolic crosstalk

The TME creates a complex metabolic ecosystem wherein lactate produced by one cell type drives lactylation in neighboring cells. Tumor-derived lactate promotes MOESIN lactylation in regulatory T cells, establishing paracrine lactylation as a mechanism for immune modulation (42). Lactylation-driven METTL3-mediated RNA N6-methyladenosine (m6A) modification promotes immunosuppression of tumor-infiltrating myeloid cells, revealing a cascade from metabolic signal through epigenetic modification to RNA-level regulation (55). Previous studies have extended this concept to multiple immune cell types. Cai et al (56) demonstrated that lactylation-driven nuclear protein 1 promotes immunosuppression of tumor-infiltrating macrophages in hepatocellular carcinoma, while Huang et al (57) showed that signal transducer and activator of transcription 5 promotes programmed death-ligand 1 (PD-L1) expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. De Leo et al (58) demonstrated that glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma, with mechanistic evidence linking glycolytic flux to PD-L1 expression.

Cancer-associated fibroblasts (CAFs) represent a major source of lactate in many tumors. Li et al (59) demonstrated that CAF-secreted lysyl oxidase promotes PD-L1 expression via histone lactylation and regulates tumor epithelial-mesenchymal transition (EMT) through TGFβ/insulin-like growth factor 1 signaling in gastric cancer. Kong et al (60) showed that histone lactylation-related genes correlate with the molecular patterns and functions of CAFs in clear cell renal cell carcinoma. The metabolic coupling between CAFs and cancer cells creates a 'lactate shuttle' wherein CAF-derived lactate fuels oxidative metabolism in adjacent cancer cells while simultaneously engaging epigenetic regulation. Recent evidence indicates that CAF-derived lactate induces oxaliplatin treatment resistance by promoting cancer stemness via anthrax toxin receptor 1 (ANTXR1) lactylation in colorectal cancer (61), and CAFs promote epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance via the collagen triple helix repeat containing 1/glycolysis/H3K18la positive feedback loop (62). Importantly, the relative contribution of tumor cell-autonomous vs. stroma-derived lactate to the overall lactylation landscape remains debated, with evidence supporting context-dependent predominance of each source. This debate is also influenced by model systems: CAF-derived lactate effects are largely shown in co-culture or xenografts (61,62), whereas immune-cell lactylation is mostly studied in isolated populations (42,55-58). Direct isotope tracing of tumor- vs. stroma-derived lactate into defined lactylation sites in patient tumors is still lacking. CAF-derived lactate also contributes to oxaliplatin resistance via stemness regulation (61).

Spatial and single-cell heterogeneity

Emerging evidence indicates that lactylation exhibits marked spatial heterogeneity within tumor tissues and CSC niches. Histone lactylation-derived long intergenic non-protein coding RNA 1127 (LINC01127) promotes the self-renewal of glioblastoma stem cells via cis-regulation of mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) to activate the c-Jun N-terminal kinase (JNK) pathway, establishing that lactylation signatures are enriched within CSC populations compared with differentiated tumor cells (63). Feng et al (8) performed comprehensive lactylome analysis in liver cancer stem cells, unveiling lactylation-dependent mechanisms of stemness remodeling and identifying pathways specifically activated in the CSC compartment. Pan et al (64) showed that demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells, providing pharmacological evidence that CSC-specific lactylation is therapeutically accessible.

Single-cell transcriptomic analyses have begun to resolve lactylation heterogeneity. Zhang et al (65) developed a comprehensive gene signature linking hypoxia, glycolysis and lactylation in gastric cancer through integration of bulk and single-cell RNA-seq data, identifying cell subpopulations with distinct lactylation-associated transcriptional programs. Lu et al (66) integrated single-cell and bulk RNA-sequencing data to reveal molecular subtypes based on lactylation-related genes in glioma, demonstrating prognostic and therapeutic response associations. Yu et al (67) performed single-cell RNA sequencing and spatial transcriptomics analyses to reveal how hepatic stellate cells promote hepatocellular carcinoma development by regulating histone lactylation. Recent studies have integrated single-cell and spatial transcriptomics to identify lactylation-associated tumor cell clusters and define prognostic risk models in glioblastoma (68) and to reveal the association between histone lactylation and cisplatin resistance in bladder cancer (69). A critical insight from these studies is that lactylation heterogeneity correlates with therapeutic response: Tumor regions with high lactylation signatures exhibit increased resistance to chemotherapy and immunotherapy. However, current single-cell approaches infer lactylation activity from gene expression rather than directly measuring the modification, representing a technical limitation that will require advances in single-cell proteomics to overcome. Therefore, current claims of spatial lactylation heterogeneity should be regarded as hypothesis-generating. Lactylation-associated signatures may reflect general hypoxia, glycolysis, or CSC programs rather than lactylation itself (65,66,68,69). Future integration of spatial transcriptomics with lactylation-specific imaging approaches will be essential to fully resolve the spatial architecture of the lactylation landscape in the tumor microenvironment.

Lactylation-mediated epigenetic regulation of cancer stemness

Lactylation acts as a metabolic-epigenetic coupling effector governing cancer stem cell (CSC) maintenance, self-renewal and plasticity. The regulatory landscape encompasses histone mark deposition at pluripotency gene loci, non-histone protein modification in core signaling cascades, and lactylation-driven EMT and CSC plasticity. Cancer type-specific lactylation patterns further reveal the contextual dependency of this modification. Table I summarizes key lactylation targets, their downstream effectors, and functional consequences in CSC regulation.

Table I

Key studies on lactylation-mediated epigenetic regulation of cancer stemness.

Table I

Key studies on lactylation-mediated epigenetic regulation of cancer stemness.

First author/s, yearMechanism categoryCancer typeLactylation target (site/mark) Mechanism/pathwayFunctional consequence on stemnessValidation model/key note(Refs.)
Lv et al, 2025Histone lactylation-mediatedPancreatic cancerH3K9la, H3K18laα2δ1-mediated Ca2+ signaling → SIRT4 upregulation → ENO1 deacetylation (K358) → glycolysis → histone lactylationPromotes TIC stemness via epigenetic reprogrammingPDAC organoids, in vivo limiting dilution(9)
Zhao et al, 2026Gastric adenocarcinomaH3K27laPSMD14-mediated PFKFB2 deubiquitination → enhanced glycolysis/lactate → H3K27la at stemness promotersDrives cancer stemnessGastric cancer cells, in vivo limiting dilution(11)
Li et al, 2023GlioblastomaHistone lactylation-derived LINC01127NF-κB-induced lactate → H3la → LINC01127 → cis-activation of MAP4K4 → JNK/NF-κBPromotes GSC self-renewal and orthotopic tumor growthPatient-derived GSCs, intracranial xenograft(63)
Li et al, 2025GliomaH3K18la at VRK1 promoterLactate → H3K18la → VRK1 upregulation → YBX1 stabilization → YBX1/SOX2 axisEnhances GSC stemness and proliferationGSC lines, limiting dilution assay(70)
Liu et al, 2025HCCHistone lactylation at MCM7 promoterHistone lactylation → MCM7 transcription → DNA replication licensingMaintains LCSC stemness and radio-resistanceLCSCs, irradiation models(71)
Zhang et al, 2025Colon cancerHistone lactylationHypoxia → elevated lactate → histone lactylation at stemness gene promotersEnhances colon CSC stemness under hypoxiaColon cancer cells, hypoxia exposure(72)
Nguyen et al, 2025Intestinal organoidsHistone lactylationLactate → histone lactylation → epigenetic reprogramming of differentiation genesControls CSC plasticity and self-renewal/differentiation balanceMouse intestinal organoids, primary human tumor organoids(73)
Zhao et al, 2025NSCLCHistone lactylation-driven YTHDF2 upregulationHistone lactylation → YTHDF2 → recognition of m6A-SFRP2 → SFRP2 silencing → glycolysis/stemnessPromotes NSCLC glycolysis and stemnessNSCLC cells, m6A-seq(77)
Chen et al, 2025Salivary adenoid cystic carcinomaH3K18laTumor-associated Schwann cells → IGF2/IGF1R → glycolysis → H3K18la at stemness promotersInduces stem-like reprogrammingSACC cells, xenograft(80)
Shi et al, 2025Lung cancerH3K14laCSC-derived exosomal Mir100hg → ALDOA upregulation → lactate → H3K14la → 169 metastasis-related genesEnhances metastatic activity in non-CSCsLung cancer cells, exosome transfer model(81)
Yao and Yang, 2024HCCHistone lactylationHypoxia → lactate → histone lactylation → stemness/glycolysis gene activation; reversed by Glypican-3 knockdownDrives hypoxia-induced stemnessHCC cells under hypoxia(85)
Miao et al, 2023Non-histone lactylation-mediatedColorectal cancerβ-catenin lactylationHypoxia → β-catenin lactylation → Wnt pathway activationPromotes cell proliferation and stemnessColon cancer cells, TOPFlash reporter(54)
He et al, 2025Colorectal cancerANTXR1 K453 lactylationCAF-derived lactate → ANTXR1 K453la → ANTXR1 stabilization → RhoC/ROCK1/SMAD5 pathwayPromotes CSC stemness and oxaliplatin resistanceCRC organoids, CAF co-culture(61)
Qiao et al, 2024Esophageal cancerSHMT2 lactylationHypoxia → SHMT2 lactylation → SHMT2 enzymatic activity → glycolysis feed-forwardFacilitates glycolysis and stemnessESCC cells, sphere formation(74)
Li et al, 2024Esophageal carcinomaAxin1 lactylationHypoxia → Axin1 lactylation → glycolysis enhancementPromotes glycolysis and stemnessESCC cells, xenograft(75)
Yan et al, 2024NSCLCSOX9 lactylationHypoxia → glycolysis → SOX9 lactylation → SOX9 transcriptional activityPromotes NSCLC cell stemness, migration, invasionNSCLC cells, tumorsphere assay(76)
Yuan et al, 2026TNBCPOLR2A lactylation (inhibition)BPHL → POLR2A lactylation inhibition → BARD1-mediated ubiquitination/R-loop resolution → β-catenin nuclear translocationSustains CSC stemness; expands CSC compartmentTNBC cell lines, patient-derived xenograft(78)
Zhou et al, 2025GliomaPTBP1 lactylationPTBP1 lactylation → PFKFB4-driven glycolysis → lactate feed-forward → histone lactylationPromotes GSC maintenance; forms vicious metabolic-epigenetic cycleGSCs, glycolysis flux assay(83)
Liu et al, 2025Breast cancerZMIZ1 K843 lactylationLactate → ZMIZ1 lactylation (suppresses SUMOylation/ubiquitination) → ZMIZ1 binding to Nanog → Nanog transcription (OCT4, NPC2)Induces tamoxifen resistance via stemness and cholesterol uptakeER+ breast cancer cells, xenograft(86)
Feng et al, 2024Histone and non-histone lactylation-mediated (dual)HCC (LCSCs)Global lactylome (H3K56la; ALDOA K230/322la)H3K56la elevates gene transcription; ALDOA lactylation weakens ALDOA-DDX17 binding → liberates DDX17Maintains LCSC stemness; defines LCSC-specific lactylation signaturePrimary LCSCs vs. differentiated HCC cells(8)

[i] ALDOA, aldolase A; ANTXR1, anthrax toxin receptor 1; BARD1, BRCA1-associated RING domain 1; BPHL, biphenyl hydrolase-like protein; CAF, cancer-associated fibroblast; CRC, colorectal cancer; CSC, cancer stem cell; DDX17, DEAD-box helicase 17; ENO1, enolase 1; ER+, estrogen receptor-positive; ESCC, esophageal squamous cell carcinoma; GSC, glioma stem cell; H3K9la, H3K18la, H3K27la, H3K56la, H4K12la, histone H3/H4 lysine lactylation; HCC, hepatocellular carcinoma; IGF1R, insulin-like growth factor 1 receptor; IGF2, insulin-like growth factor 2; JNK, c-Jun N-terminal kinase; LCSC, liver cancer stem cell; LINC01127, long intergenic non-protein coding RNA 1127; MAP4K4, mitogen-activated protein kinase kinase kinase kinase 4; MCM7, minichromosome maintenance complex component 7; m6A, N6-methyladenosine; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NPC2, Niemann-Pick disease type C2; NSCLC, non-small cell lung cancer; OCT4, octamer-binding transcription factor 4; PDAC, pancreatic ductal adenocarcinoma; PFKFB4, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4; POLR2A, RNA polymerase II subunit A; PSMD14, proteasome 26S subunit non-ATPase 14; PTBP1, polypyrimidine tract-binding protein 1; ROCK1, Rho-associated coiled-coil containing protein kinase 1; SACC, salivary adenoid cystic carcinoma; SFRP2, secreted frizzled related protein 2; SHMT2, serine hydroxymethyltransferase 2; SIRT4, sirtuin 4; SOX2, SOX9, SRY-box transcription factors; TIC, tumor-initiating cell; TNBC, triple-negative breast cancer; VRK1, vaccinia-related kinase 1; Wnt, wingless-related integration site; YBX1, Y-box binding protein 1; YTHDF2, YTH N6-methyladenosine RNA binding protein F2; ZMIZ1, zinc finger MIZ-type containing 1.

Histone lactylation in CSC pluripotency and self-renewal

Histone lactylation directly couples glycolytic flux to the transcriptional programs that sustain CSC identity. In glioblastoma stem cells (GSCs), Li et al (63) demonstrated that histone lactylation-derived LINC01127 promotes self-renewal via cis-regulation of MAP4K4 to activate the JNK pathway, establishing a mechanistic link between lactate metabolism and GSC maintenance. Complementing this finding, Li et al (70) recently showed that histone lactylation-driven upregulation of vaccinia-related kinase 1 promotes stemness and proliferation of GSCs through the Y-box binding protein 1 (YBX1)/SRY-box transcription factor 2 (SOX2) axis, further expanding the epigenetic network controlling glioma stemness.

Beyond glioblastoma, histone lactylation-mediated stemness regulation operates across diverse tumor types. In hepatocellular carcinoma (HCC), Liu et al (71) demonstrated that histone lactylation facilitates minichromosome maintenance complex component 7 (MCM7) expression to sustain stemness and radio-resistance, while SIRT4 was identified by Lv et al (9) as a promoter of pancreatic cancer stemness through enhancing histone lactylation and epigenetic reprogramming stimulated by calcium signaling. In colorectal cancer, Zhang et al (72) showed that hypoxia facilitates colon cancer cell stemness via histone lactylation. Notably, a study by Nguyen et al (73) provided functional evidence that lactate controls cancer stemness and plasticity through epigenetic regulation in intestinal organoid models, demonstrating that lactate directly influences the balance between self-renewal and differentiation. Collectively, these findings establish histone lactylation as a conserved epigenetic node for CSC maintenance, though the specific histone marks [(H3K9la, H3K18la, H4K12la, histone H3 lysine 14 lactylation (H3K14la)] and downstream target genes vary substantially across cancer types.

Non-histone protein lactylation in stemness maintenance

While histone lactylation provides a global epigenetic framework, non-histone protein lactylation directly modulates the activity of key stemness-regulating factors. In esophageal cancer cells, Qiao et al (74) demonstrated that hypoxia-induced serine hydroxymethyltransferase 2 (SHMT2) protein lactylation facilitates glycolysis and stemness, revealing a feed-forward loop wherein metabolic enzyme lactylation reinforces the glycolytic phenotype. Similarly, Li et al (75) showed that hypoxia exposure induces Axin1 lactylation to promote glycolysis in esophageal carcinoma cells, establishing that lactylation of signaling proteins can rewire metabolic and stemness pathways simultaneously.

Critical insights into non-histone lactylation mechanisms have emerged from studies of transcription factor regulation. Yan et al (76) demonstrated that hypoxia promotes non-small cell lung cancer (NSCLC) cell stemness, migration, and invasion via lactylation of SOX9, a master transcription factor for stem cell identity. In gastric cancer, Zhao et al (77) revealed that histone lactylation-driven YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) promotes NSCLC cell glycolysis and stemness by recognizing m6A modification of secreted frizzled-related protein 2, demonstrating crosstalk between lactylation and RNA epigenetic modifications in stemness control. More recently, Yuan et al (78) showed that biphenyl hydrolase-like promotes triple-negative breast cancer stemness by resolving R-loops via RNA polymerase II subunit A (POLR2A) lactylation inhibition and BARD1-mediated ubiquitination, revealing a sophisticated interplay between lactylation, transcriptional regulation and genome stability in CSC maintenance. A comparative analysis across these studies reveals that non-histone lactylation predominantly targets either metabolic enzymes (SHMT2, Axin1) or stemness-associated transcription factors (SOX9, YTHDF2), suggesting context-dependent selection of lactylation substrates.

Lactylation in EMT and metastatic stemness

The acquisition of CSC traits during EMT is intimately linked to lactylation-dependent gene regulation. In prostate carcinoma, Fiaschi et al (79) provided early evidence that carbonic anhydrase IX from CAFs drives EMT, establishing that stromal-derived metabolic signals influence cancer cell plasticity. More recent work has directly implicated lactylation in this process. In colorectal cancer, CAF-derived lactate promotes cancer stemness through ANTXR1 lactylation (61), establishing a paracrine mechanism whereby stromal metabolic signals drive CSC plasticity.

Tumor-associated stromal cells beyond CAFs also contribute to lactylation-mediated stemness reprogramming. Chen et al (80) found that tumor-associated Schwann cells promote salivary adenoid cystic carcinoma stem-like reprogramming via insulin-like growth factor 2 (IGF2)/insulin-like growth factor 1 receptor-induced histone H3K18 lactylation, expanding the repertoire of stromal cell types that orchestrate CSC plasticity through lactylation. In lung cancer, Shi et al (81) demonstrated that exosomal lncRNA Mir100hg from lung CSCs activates H3K14 lactylation to enhance metastatic activity in non-stem lung cancer cells, revealing that CSCs themselves can propagate stemness-associated epigenetic marks to neighboring cells. These findings collectively indicate that lactylation-mediated EMT and metastatic stemness operate through both autocrine and paracrine mechanisms, with the relative contribution of each mode likely determined by tumor type and microenvironmental context.

Lactylation-mediated control of CSC plasticity and dormancy

The remarkable plasticity of CSCs, their ability to transition between quiescent and proliferative states and to dedifferentiate from non-stem populations, is increasingly recognized as being regulated by lactylation. Nguyen et al (73) provided foundational evidence that lactate controls cancer stemness and plasticity through epigenetic regulation, showing in organoid systems that lactate exposure promotes a dedifferentiated, stem-like state. This plasticity is not unidirectional; rather, lactylation levels appear to define a rheostat that determines the position of cancer cells along the differentiation continuum.

Hypoxia serves as a dominant driver of lactylation-mediated plasticity. In colon cancer, Zhang et al (72) demonstrated that hypoxia facilitates stemness via histone lactylation. Hypoxia-induced β-catenin lactylation promotes colorectal cancer cell proliferation and stemness via Wnt signaling (54), as introduced in the oncogenic and hypoxic regulation section, reinforcing the convergence of hypoxia, lactylation and Wnt signaling in CSC plasticity. Wang et al (82) further expanded this concept by showing that Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in neuroendocrine prostate cancer, although direct lactylation involvement in this context requires additional investigation. A critical unresolved question is whether lactylation actively maintains the dormant CSC population or primarily drives the transition from dormancy to proliferation, a distinction with significant therapeutic implications given that dormant CSCs are thought to mediate minimal residual disease and late recurrence.

Cancer type-specific lactylation programs in CSCs

The lactylation landscape exhibits marked heterogeneity across types of cancer and CSC subpopulations. Feng et al (8) performed comprehensive lactylome analysis in liver CSCs, unveiling lactylation-dependent mechanisms of stemness remodeling and identifying pathways specifically activated in the CSC compartment compared with differentiated HCC cells. This study revealed that liver CSCs exhibit distinct lactylation signatures enriched for proteins involved in RNA splicing and metabolic adaptation. In glioma, Zhou et al (83) demonstrated that polypyrimidine tract-binding protein 1 (PTBP1) lactylation promotes GSC maintenance through PFKFB4-driven glycolysis, while Tang et al (84) deciphered the lactylation landscape in glioma to establish a novel gene signature predicting patient survival.

Emerging evidence has identified cancer type-specific lactylation regulators. In pancreatic cancer, Lv et al (9) identified SIRT4 as a key promoter of stemness through enhancing histone lactylation. In HCC, Liu et al (71) showed that histone lactylation facilitates MCM7 expression, while Yao and Yang (85) demonstrated that Glypican-3 knockdown inhibits HCC cell stemness under hypoxic conditions through lactylation. In gastric cancer, PSMD14-mediated 6-phosphofructo-2-kinase/fructose-2 and 6-biphosphatase 2 (PFKFB2) deubiquitination activates H3K27 lactylation to drive cancer stemness (11), as discussed in detail in the CSC stemness as a hub for lactylation-driven multidrug resistance section. Notably, recent studies have linked lactylation to therapy resistance in a cancer type-specific manner: Liu et al (86) reported that zinc finger MIZ-type containing 1 (ZMIZ1) lactylation induces tamoxifen resistance in breast cancer through Nanog-dependent stemness regulation, whereas the ANTXR1 lactylation axis in colorectal cancer is discussed in the 'CSC stemness as a hub for lactylation-driven multidrug resistance' section in the context of CSC-mediated multidrug resistance. The PSMD14-PFKFB2-H3K27la regulatory axis driving gastric adenocarcinoma stemness is discussed in detail in the 'CSC stemness as a hub for lactylation-driven multidrug resistance' section (11). These observations support the concept that lactylation-driven stemness programs are context-dependent, suggesting that therapeutic targeting of lactylation may require cancer type-specific strategies informed by the underlying epigenetic architecture. However, many cancer type-specific programs are derived from bulk lactylome or transcriptomic signatures without direct CSC vs. non-CSC comparison using site-specific assays. The apparent heterogeneity may therefore partly reflect differences in models, lactate exposure, and detection methods rather than true cancer type-specific biology (8,63,69,73,84). Notably, several lactylation substrates described above also participate in therapeutic-resistance phenotypes in Section 5. Crosstalk with other post-translational modifications shared by stemness and drug-resistance programs is discussed comprehensively in Section 6 to avoid redundant mechanistic restatement.

Lactylation orchestrates cancer drug resistance via metabolic-epigenetic remodeling

Therapeutic failure induced by chemotherapy, targeted agents and immunotherapy is frequently fueled by CSC-associated metabolic-epigenetic plasticity. Building upon the metabolic-epigenetic cascades outlined in Sections 2-4, lactylation translates glycolytic and microenvironmental lactate signals into stable pro-survival transcriptional programs to establish multidrug resistance. Fig. 3 illustrates core regulatory networks linking lactylation to therapy resistance, including enhanced DNA repair, ferroptosis suppression, sustained stemness transcriptional programs, and reshaping of the immunosuppressive tumor microenvironment.

Metabolic-epigenetic remodeling by
lactylation drives therapy resistance through four core mechanistic
taxonomies. Lactate derived from glycolysis or the tumor
microenvironment fuels Kla on histones and non-histone proteins.
The four color-coded mechanistic branches represent the core
taxonomies of lactylation-mediated resistance: Enhanced DNA-damage
repair, including homologous recombination enhancement and DNA
repair pathway activation; Ferroptosis evasion, including
glutathione biosynthesis upregulation and lipid peroxidation
neutralization; Oncogenic stem-cell transcriptional programming,
including stemness transcription factor lactylation and
pluripotency gene activation; and immunosuppressive
microenvironment remodeling, including PD-L1 stabilization,
immunosuppressive myeloid cell polarization and CD8+ T cell
dysfunction. These mechanistic branches converge to confer
resistance across chemotherapy, targeted therapy and immunotherapy,
ultimately driving CSC-originated multidrug resistance and tumor
relapse Kla, lysine lactylation; CSC, cancer stem cell.

Figure 3

Metabolic-epigenetic remodeling by lactylation drives therapy resistance through four core mechanistic taxonomies. Lactate derived from glycolysis or the tumor microenvironment fuels Kla on histones and non-histone proteins. The four color-coded mechanistic branches represent the core taxonomies of lactylation-mediated resistance: Enhanced DNA-damage repair, including homologous recombination enhancement and DNA repair pathway activation; Ferroptosis evasion, including glutathione biosynthesis upregulation and lipid peroxidation neutralization; Oncogenic stem-cell transcriptional programming, including stemness transcription factor lactylation and pluripotency gene activation; and immunosuppressive microenvironment remodeling, including PD-L1 stabilization, immunosuppressive myeloid cell polarization and CD8+ T cell dysfunction. These mechanistic branches converge to confer resistance across chemotherapy, targeted therapy and immunotherapy, ultimately driving CSC-originated multidrug resistance and tumor relapse Kla, lysine lactylation; CSC, cancer stem cell.

Conventional chemotherapy resistance

Histone and non-histone lactylation mediates chemotherapeutic resistance via three predominant effector axes: Enhancing DNA-damage repair, repressing ferroptotic cell death and activating stemness-related survival signaling. In colorectal cancer, Deng et al (87) demonstrated that histone lactylation enhances glutamate-cysteine ligase catalytic subunit (GCLC) expression, thereby inhibiting ferroptosis and promoting chemoresistance of cancer stem cells. Mechanistically, elevated lactylation at H3K18 loci drives GCLC transcription, increasing glutathione biosynthesis and neutralizing chemotherapy-induced lipid peroxidation. Complementing this finding, Zhao et al (88) showed that lncRNA BASP1-AS1 drives poly(rC)-binding protein 2 (PCBP2) K115 lactylation to suppress ferroptosis and confer oxaliplatin resistance in gastric cancer. The lactylation-stabilized PCBP2 enhances antioxidant capacity, demonstrating convergent evolution of lactylation-mediated ferroptosis evasion across gastrointestinal malignancies.

In ovarian cancer, histone lactylation has been implicated in cisplatin resistance through multiple pathways. Gao et al (89) reported that H3K18la facilitates transformer 2 alpha homolog-mediated alternative splicing of SCL/TAL1 interrupting locus, suppressing ferroptosis and reducing cisplatin sensitivity. Sun et al (90) further established that targeting platinum-resistant ovarian cancer can be achieved by disrupting histone and RAD51 lactylation, with combined approaches showing therapeutic promise. Mechanistically, RAD51 lactylation enhances homologous recombination repair efficiency, directly counteracting cisplatin-induced DNA crosslinks. A critical comparison across these studies reveals that lactylation promotes chemoresistance primarily by either i) enhancing DNA repair capacity, ii) suppressing ferroptosis, or iii) activating stemness programs, with cancer type-specific predominance of each mechanism. A further limitation is that many chemoresistance studies use single agents, short-term viability assays, or established cell lines; fewer test whether lactylation inhibition reverses resistance in patient-derived organoids or established tumors (28,87,89,91). Studies using genetic or site-specific perturbation provide stronger causal evidence than those relying only on lactate-lowering agents.

In glioblastoma, lactylation confers temozolomide (TMZ) resistance through distinct epigenetic mechanisms. Yue et al (91) demonstrated that histone H3K9 lactylation confers TMZ resistance via LUC7-like 2 pre-mRNA splicing factor-mediated MutL homolog 1 intron retention, leading to mismatch repair deficiency. Importantly, Zou et al (28) showed that SIRT6-mediated delactylation of H3K9 inhibits MGMT transcription and reverses TMZ resistance, establishing that targeting the lactylation-delactylation balance represents a therapeutically accessible strategy. In bladder cancer, Li et al (69) performed single-cell transcriptome analysis revealing the association between histone lactylation and cisplatin resistance, identifying cell subpopulations with elevated lactylation signatures that exhibit increased chemoresistance. These findings collectively establish lactylation as a conserved driver of chemoresistance, though the specific histone marks and downstream effectors vary substantially across tumor types and chemotherapeutic agents.

Targeted therapy resistance

Lactylation-mediated resistance extends to molecularly targeted agents, including EGFR inhibitors, B-Raf proto-oncogene (BRAF) inhibitors, lenvatinib and enzalutamide. In NSCLC, Dai et al (92) demonstrated that nicotinamide N-methyltransferase (NNMT) promotes acquired EGFR-TKI resistance by forming early growth response protein 1 and lactate-mediated double positive feedback loops. Mechanistically, lactate accumulation drives H3K18 lactylation at NNMT promoter regions, creating a self-reinforcing cycle that sustains resistance. Complementing this finding, Gan et al (10) identified a tumor-derived lactate/ENO1 lactylation feedback loop that facilitates osimertinib resistance in lung adenocarcinoma. ENO1 lactylation enhances its enzymatic activity, further increasing lactate production and establishing a feed-forward loop that maintains resistance even in the presence of EGFR inhibition.

In melanoma, Li et al (93) demonstrated that lactylation of lysine-specific demethylase 1 (LSD1) represents an acquired epigenetic vulnerability of BRAF inhibitor/MEK inhibitor-resistant melanoma. LSD1 lactylation alters its substrate specificity and chromatin occupancy, driving a transcriptional program that bypasses MAPK pathway inhibition. This finding is particularly significant as it reveals that resistance-conferring lactylation events can occur on non-histone epigenetic regulators, expanding the mechanistic repertoire of lactylation-mediated resistance. In HCC, Lu et al (94) showed that lactylation-driven insulin-like growth factor 2 mRNA-binding protein 3-mediated serine metabolism reprogramming and RNA m6A modification promote lenvatinib resistance. The integration of lactylation with RNA epigenetic modifications represents a sophisticated multi-layered resistance mechanism. Dong et al (95) further demonstrated that lactylation-driven HECT domain E3 ubiquitin protein ligase 2 limits the response of HCC to lenvatinib, while Zeng et al (96) established that histone lactylation promotes multidrug resistance in HCC by forming a positive feedback loop with phosphatase and tensin homolog (PTEN). A notable insight across these studies is that lactylation-mediated targeted therapy resistance frequently involves positive feedback loops that amplify the initial resistance signal, making therapeutic intervention more challenging once established.

In prostate cancer, lactylation contributes to enzalutamide resistance through multiple mechanisms. Chen et al (97) identified solute carrier family 4 member 4 as a novel driver of enzalutamide resistance, with mechanistic links to lactate metabolism and histone lactylation. Sun et al (98) further demonstrated that lysine demethylase 5B-driven glucose metabolic reprogramming promotes enzalutamide resistance via the lactate/heterogeneous nuclear ribonucleoprotein A1 lactylation/androgen receptor splice variant 7 axis. The conversion of metabolic reprogramming to alternative splicing regulation through lactylation illustrates the remarkable adaptability of resistance mechanisms.

Immunotherapy resistance

Lactylation plays an increasingly recognized role in driving resistance to immune checkpoint inhibitors (ICIs) by remodeling the tumor immune microenvironment toward immunosuppression. Tong et al (99) reported dual effects of serine/glycine-free diet in enhancing antitumor immunity while promoting evasion via PD-L1 lactylation, revealing that metabolic interventions can paradoxically induce resistance through lactylation-dependent mechanisms. In HCC, Liu et al (100) showed that lactylation-driven major vault protein (MVP) upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation. MVP lactylation stabilizes PD-L1 protein, reducing its turnover and maintaining high surface expression even in the presence of programmed cell death protein 1 (PD-1) blockade.

In pancreatic cancer, Yang et al (4) demonstrated that histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression, creating a metabolic-epigenetic barrier to effective immunotherapy. Mechanistically, elevated H3K18 lactylation drives expression of cholesterol biosynthesis genes, altering membrane lipid composition of immune cells and impairing T cell function. Chen et al (101) further showed that targeting lactylation and the signal transducer and activator of transcription 3/CCL2 axis overcomes immunotherapy resistance in pancreatic ductal adenocarcinoma, providing a rational combination strategy. Sun et al (102) extended these findings by demonstrating that elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic cancer, with high lactylation signatures correlating with poor response to anti-PD-1 therapy.

In lung cancer, Wang et al (103) established that H3K9 lactylation in malignant cells facilitates CD8+ T cell dysfunction and poor immunotherapy response. Zhang et al (104) similarly showed that H3K18 lactylation potentiates immune escape of NSCLC. A critical insight emerging from these studies is that lactylation promotes immune checkpoint inhibitor resistance primarily through three convergent mechanisms: i) Direct upregulation of PD-L1 expression, ii) induction of immunosuppressive macrophage and myeloid-derived suppressor cell polarization and iii) impairment of CD8+ T cell metabolic fitness and cytotoxic function.

CSC stemness as a hub for lactylation-driven multidrug resistance

CSCs represent a central reservoir for multidrug resistance, and lactylation serves as a key epigenetic driver of CSC maintenance across therapy contexts. Li et al (86) demonstrated that ZMIZ1 lactylation induces tamoxifen resistance in breast cancer through increasing transcriptional activity of Nanog to impact cell stemness. This finding mechanistically links lactylation to pluripotency factor regulation, showing that lactylation directly enhances Nanog-driven transcriptional programs that sustain CSC identity. In colorectal cancer, the ANTXR1 lactylation axis illustrates how microenvironment-derived signals converge on CSC maintenance to confer resistance (61); the upstream CAF-lactate mechanism is described in the lactylation in EMT and metastatic stemness section. This finding is conceptually important because it shows that lactylation-driven multidrug resistance need not arise from cell-autonomous metabolic rewiring; instead, the tumor microenvironment can impose a lactylation-dependent CSC state that subsequently confers resistance to mechanistically distinct agents. This paracrine mode of resistance is consistent with the integrated circuit model proposed below, in which therapy-induced stromal and tumor-derived lactate feed into a self-reinforcing CSC-resistance loop (61).

In gastric cancer, Zhao et al (11) revealed that PSMD14-mediated PFKFB2 deubiquitination activates H3K27 lactylation to drive cancer stemness. This study elegantly demonstrates crosstalk between ubiquitination and lactylation pathways, showing that PSMD14 stabilizes PFKFB2 to increase glycolytic flux, which in turn elevates lactate production and H3K27 lactylation at stemness gene promoters. In hepatocellular carcinoma, Zeng et al (96) showed that histone lactylation promotes multidrug resistance by forming a positive feedback loop with PTEN. PTEN loss further activates protein kinase B signaling, which upregulates glycolysis and lactate production, creating a self-reinforcing cycle. Notably, the convergence of multiple resistance mechanisms on CSC maintenance suggests that targeting lactylation within the CSC compartment might produce more durable therapeutic responses than targeting individual resistance pathways, although this hypothesis remains to be tested prospectively.

Comparative analysis across these studies reveals that lactylation-driven multidrug resistance operates through an integrated circuit wherein: i) Chemotherapy induces metabolic stress and lactate accumulation, ii) elevated lactylation activates stemness-associated transcriptional programs, iii) CSC expansion drives resistance to diverse therapeutic agents and iv) therapy-induced cell death releases additional lactate, perpetuating the cycle. This model explains why lactylation signatures correlate with resistance to mechanistically distinct drugs and suggests that interrupting this cycle at the level of lactate production, lactylation deposition, or stemness gene activation may overcome multidrug resistance.

Clinical correlations and therapeutic implications

The translational relevance of lactylation in drug resistance is supported by retrospective clinical correlation studies across multiple types of cancer. High H3K18 lactylation levels have been associated with poor prognosis in epithelial ovarian cancer and with reduced response to platinum-based chemotherapy in retrospective cohorts (105). In pancreatic cancer, elevated protein lactylation has been associated with therapeutic resistance and poor survival, and lactylation signatures have been reported to predict response to gemcitabine-based regimens in retrospective analyses (102). In glioblastoma, lactylation-associated gene signatures have been associated with stratification by TMZ response in retrospective cohorts, with high lactylation scores associated with reduced survival and increased recurrence risk (84).

Several studies have established prognostic signatures based on lactylation-related genes that predict treatment responsiveness. In bladder cancer, Zhao et al (106) developed a lactylation prognostic signature identifying 7-dehydrocholesterol reductase (DHCR7) as a modulator of chemoresistance and immunotherapy efficacy. In lung adenocarcinoma, lactylation-related gene signatures predict prognosis and treatment response in radiation-resistant NSCLC (107). In colorectal cancer, lactylation-based prognostic models predict chemotherapeutic efficacy and guide treatment selection (108). Several retrospective studies have reported prognostic signatures based on lactylation-related genes that are associated with treatment responsiveness. In bladder cancer, Zhao et al (106) developed a lactylation prognostic signature identifying 7-dehydrocholesterol reductase (DHCR7) as a modulator of chemoresistance and immunotherapy efficacy. In lung adenocarcinoma, lactylation-related gene signatures have been associated with prognosis and treatment response in radiation-resistant NSCLC (107). In colorectal cancer, lactylation-based prognostic models have been reported to predict chemotherapeutic efficacy and guide treatment selection in retrospective cohorts (108). These clinical correlation studies provide a foundation for developing lactylation-based biomarkers for patient stratification, though prospective validation in clinical trial cohorts remains necessary before clinical implementation. Nonetheless, most signatures are retrospective, platform-dependent, and not externally validated. Lactylation marks are often measured by bulk immunohistochemistry or inferred from RNA, which may not capture CSC-specific or spatial heterogeneity. Prospective trials with pre-specified assays are required (84,105,106,108).

Crosstalk between lactylation and other post-translational modifications

The functional output of protein lactylation in cancer stemness and drug resistance is not executed in isolation but rather integrated into a complex PTM network. Crosstalk between lactylation and other PTMs, including acetylation, ubiquitination, phosphorylation and short-chain acylations, adds regulatory sophistication to metabolic-epigenetic programming. Table II summarizes key examples of PTM crosstalk and their functional consequences in therapy resistance.

Table II

Crosstalk between lactylation and other post-translational modifications in cancer regulation.

Table II

Crosstalk between lactylation and other post-translational modifications in cancer regulation.

First author/s, yearCrosstalk typePTM TypeTarget protein/residue(s)Regulation directionModification site(s)Functional consequence(Refs.)
Zhang et al, 2019CompetitiveAcetylationHistones (general)Competitive occupancyUnspecified lysine residuesLactylation responds to while acetylation responds to acetyl-CoA; both modifications compete for the same histone lysine residues(12)
Huang et al, 2026 Cooperative/Positive feedback Acetylation/PhosphorylationGCN5/ERKPositive feedback loopGCN5: lactylation; ERK: phosphorylationGCN5 lactylation enhances ERK activity; ERK phosphorylation promotes GCN5 acetylation and nuclear translocation, accelerating lactate-driven cancer progression(37)
Yang et al, 2025HierarchicalAcetylationHDAC1 (K432)Hierarchical regulationK432HDAC1 lactylation inhibits its deacetylase activity, conferring ferroptosis resistance and globally reprogramming the acetylation landscape(110)
Xiong et al, 2022 Indirect/sequentialLactylation + RNA m6A modificationMETTL3Indirect regulationUnspecifiedLactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells(55)
Sun et al, 2023 Indirect/sequentialLactylation + RNA m6A modificationMETTL16 (K229)Sequential crosstalk with SIRT2K229METTL16 lactylation promotes cuproptosis via m6A modification on FDX1 mRNA; SIRT2 antagonizes this lactylation(112)
Rao et al, 2025 Indirect/sequentialLactylation + Ubiquitination (independent)cGAS, (K21 K415) Ubiquitin-independent degradationK21, K415Lactylation promotes proteasomal degradation of cGAS bypassing ubiquitin, repressing interferon production and promoting tumor growth(113)
Fu et al, 2023 Integrative/multi-PTM framework Crotonylation/Succinylation (comparison)HistonesComplementary readoutsUnspecifiedHistone acylation biomarkers (lactylation, crotonylation, succinylation) provide complementary information on cellular metabolic states(111)
Lao et al, 2024 Integrative/multi-PTM frameworkMultiple PTMs (integrative framework)Various targetsCombinatorial PTM codeMultiple residuesDeciphering multi-PTM-associated regulatory patterns and therapeutic opportunities in hepatocellular carcinoma(114)
Chen et al, 2025 Integrative/multi-PTM frameworkMultiple PTMs (integrative analysis)Various targetsNetwork-basedMultiple residuesIntegrative analysis of bulk RNA-seq, scRNA-seq and spatial transcriptomics to identify PTM-related molecular subtypes and therapeutic responses in HCC(115)

[i] PTM, post-translational modification; Ac, acetylation; cGAS, cyclic GMP-AMP synthase; ERK, extracellular signal-regulated kinase; FDX1, ferredoxin 1; GCN5, general control nonderepressible 5 (KAT2A); HCC, hepatocellular carcinoma; HDAC1, histone deacetylase 1; Kla, lysine lactylation; m6A, N6-methyladenosine; METTL3/16, methyltransferase-like 3/16; scRNA-seq, single-cell RNA sequencing; SIRT2, sirtuin 2; Ub, ubiquitination.

Reciprocal regulation with acetylation

Acetylation represents the most extensively studied PTM that functionally intersects with lactylation. Both modifications target lysine residues and are regulated by overlapping enzymatic machineries, yet they convey distinct metabolic signals. Zhang et al (12) demonstrated that histone lactylation occurs in response to elevated lactate levels, whereas acetylation responds primarily to acetyl-CoA availability, establishing that different metabolic inputs drive these modifications. Competitive occupancy of the same lysine residues by lactylation vs. acetylation has been documented on histones, suggesting that the relative abundance of each modification determines transcriptional outcomes.

The functional interplay extends beyond competitive exclusion. Huang et al revealed a GCN5-ERK lactylation-phosphorylation amplification loop wherein GCN5-mediated lactylation enhances ERK activity, which in turn promotes GCN5 acetylation and nuclear translocation (37). This positive feedback loop accelerates lactate-driven cancer progression, demonstrating that lactylation and acetylation can synergistically amplify oncogenic signaling. Chen et al (109) showed that meiotic recombination 11 homolog (MRE11) lactylation at lysine 673 promotes homologous recombination repair, while acetylation at the same residue exerts distinct regulatory effects on DNA end resection. The functional divergence between lactylation and acetylation at identical sites suggests that cells employ modification-specific readers to decode distinct metabolic states. Notably, Yang et al (110) demonstrated that HDAC1 lactylation at lysine 432 confers resistance to ferroptosis in colorectal cancer by inhibiting HDAC1 deacetylase activity, thereby altering the acetylation status of downstream targets. This represents a hierarchical crosstalk mechanism wherein lactylation of an eraser enzyme globally reprograms the acetylation landscape.

Interplay with other short-chain acyl modifications

Beyond acetylation, lactylation coexists with other short-chain acyl modifications including succinylation, crotonylation and butyrylation. These modifications utilize distinct acyl-CoA precursors and respond to different metabolic fluxes. Fu et al (111) highlighted that histone acylation biomarkers such as lactylation, crotonylation and succinylation provide complementary readouts of cellular metabolic states. The functional specificity of lactylation compared with other acylations likely derives from its unique metabolic sensor role for glycolytic flux and lactate concentration.

Emerging evidence suggests that lactylation can influence the deposition of other acyl modifications through metabolic regulation. Sun et al (112) demonstrated that methyltransferase-like 16 lactylation promotes cuproptosis via m6A modification on FDX1 mRNA, revealing crosstalk between lactylation and RNA methylation pathways. Xiong et al (55) established that lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells, indicating that lactylation can indirectly regulate RNA-level modifications. This multi-layered regulatory cascade, from metabolic signal to protein lactylation to RNA epigenetic modification, exemplifies the integrative capacity of lactylation within cellular regulatory networks. However, direct competition between lactylation and other short-chain acylations for the same lysine residues remains incompletely characterized, representing an important direction for future investigation.

Integration with ubiquitination and phosphorylation

Ubiquitination governs protein stability and degradation, and recent evidence indicates that lactylation can either promote or antagonize ubiquitin-dependent proteolysis. Rao et al (113) demonstrated that cyclic GMP-AMP synthase (cGAS) lactylation orchestrates ubiquitin-independent degradation, revealing that lactylation can bypass canonical ubiquitination pathways to regulate protein turnover. Deubiquitinase-controlled lactylation in gastric adenocarcinoma is described in the 'CSC stemness as a hub for lactylation-driven multidrug resistance' section (11). The reciprocal regulation is equally important: ubiquitination can limit lactylation by reducing substrate availability, while lactylation can protect proteins from ubiquitin-mediated degradation.

Phosphorylation represents another major PTM that functionally crosstalks with lactylation. Huang et al (37) demonstrated that the GCN5-ERK lactylation-phosphorylation loop amplifies lactate-driven cancer progression, wherein ERK phosphorylation promotes GCN5-mediated lactylation and lactylation reciprocally enhances ERK phosphorylation. Chen et al (109) showed that MRE11 lactylation is potentiated by ATM-mediated phosphorylation, coupling DNA damage signaling to metabolic status. This integration ensures that DNA repair responses are modulated according to cellular metabolic context, with potential implications for chemotherapy resistance. A critical insight emerging from these studies is that lactylation often operates within positive feedback loops with phosphorylation, creating self-reinforcing circuits that sustain oncogenic signaling and therapy resistance once established.

Combinatorial PTM code and therapeutic implications

The convergence of multiple PTMs on common target proteins generates a combinatorial PTM code that fine-tunes protein function in a context-dependent manner (114). Lactylation does not function as an isolated switch but rather as one node within an integrated PTM network that decodes metabolic, signaling and stress inputs. The crosstalk mechanisms aforementioned, including competitive occupancy, hierarchical regulation, and reciprocal feedback (11,37), collectively enable cancer cells to coordinate stemness maintenance and drug resistance across multiple regulatory layers. Therapeutically, targeting the writers, erasers, or readers of lactylation may have unintended consequences on acetylation and other PTMs given the shared enzymatic machinery. Conversely, the interconnected nature of PTM networks suggests that combination therapies simultaneously targeting multiple modification pathways may be required to overcome resistance (115). Understanding the context-specific rules governing PTM crosstalk will be essential for developing precision strategies that disrupt lactylation-driven stemness and drug resistance without perturbing essential homeostatic functions. The current PTM crosstalk literature is also uneven. Most claims derive from single-PTM perturbation experiments and few studies map lactylation and acetylation, ubiquitination, or phosphorylation on the same residue in the same model (109,110,114,115). Thus, the combinatorial PTM code remains a conceptual framework rather than a fully resolved mechanism.

Therapeutic targeting of lactylation for overcoming cancer stemness and drug resistance

Targeting the lactylation pathway has emerged as a promising therapeutic strategy to counteract cancer stemness and drug resistance. Preclinical advances demonstrate that interventions targeting lactate metabolism, lactylation writers and erasers and natural products can reverse lactylation-driven malignancy. Table III summarizes key preclinical agents and their mechanisms of action in overcoming therapy resistance.

Table III

Preclinical and clinical strategies targeting lactylation to overcome cancer stemness and drug resistance.

Table III

Preclinical and clinical strategies targeting lactylation to overcome cancer stemness and drug resistance.

First author/s, yearStrategy category Agent/intervention Target/mechanismCancer type/modelEffect on lactylationTherapeutic outcomeEvidence level(Refs.)
Krishnamoorthy et al, 2020Therapeutic strategies: targeting lactate metabolism/transportFX11LDHA inhibitorMycobacterium tuberculosis model (extrapolated to cancer)Reduces histone lactylationSuppresses tumor progressionIn vitro(116)
Sun et al, 2023OxamateLDHA inhibitorGlioblastomaSuppresses CCR8 lactylationEnhances CAR-T therapy efficacyIn vitro/animal(117)
Ge et al, 2024LDHB inhibitorLDHBLung cancerReduces mitochondrial GSH catabolism (indirect)Suppresses metastatic potentialIn vitro(118)
Lopez et al, 2023AZD3965MCT1 inhibitorB-cell malignanciesBlocks lactate transport, lowering substrate for lactylationImproves CAR-T therapyIn vitro(119)
Saulle et al, 2020MCT1/MCT4 inhibitorsMCT1 or MCT4Acute myeloid leukemiaReduces lactate availabilityImpairs leukemic proliferation, increases chemosensitivityIn vitro(120)
Bridgewater et al, 2023Synthetic catalysts + MCT inhibitorsLactate metabolismCancer cells (in vitro)Disrupts lactate poolsSynergistic anti-metabolic effectIn vitro(121)
Chen et al, 2020MSN-based nanoplatformLactate metabolism (AARS1-related pathway)Tumor modelsInterferes with lactate utilizationInduces tumor acidosis, suppresses metastasisIn vitro/animal(122)
Hu et al, 2020DRP1 targetingLactate utilization (KRAS-mutant NSCLC)Non-small cell lung cancerModulates lactate fluxReduces lactate-driven proliferationIn vitro(123)
Zhang et al, 2022ROS-activatable nanoassemblyLactate metabolism modulation; ferroptosis sensitizationTumor modelsReduces H3 lactylationEnhances ferroptosis therapyIn vitro/animal(127)
Khamoui et al, 2020Therapeutic strategies: targeting lactylation writers/erasersNuclear GTPSCS inhibitionLactyl-CoA synthetaseColon-26 cachexia modelBlocks nuclear lactyl-CoA productionSuppresses histone lactylation and tumor growthAnimal model(124)
Zeng et al, 2020Class I HDAC inhibitorsHDAC1-3 (delactylase)Hepatocellular carcinomaBlocks delactylation, increases global lactylationSynergistic anti-cancer effect (with ODC1/PKM2 inhibition)In vitro(125)
Qin et al, 2021SIRT6 inhibitorSIRT6 (delactylase)GlioblastomaPrevents H3K9 delactylationReverses temozolomide resistanceIn vitro(126)
Pan et al, 2022Therapeutic strategies: natural products DemethylzeylasteralHistone lactylationLiver cancer stem cellsInhibits H3K18la at stemness gene promotersSuppresses tumorigenicityIn vitro/animal(64)
Zhang et al, 2024EmodinMCT1Non-small cell lung cancerLowers lactate import, reduces lactylation substrateDelays tumor progressionIn vitro(128)
Xu et al, 2023Royal jelly acidH3K9la/H3K14 laHepatocellular carcinomaDirectly inhibits H3 histone lactylationSuppresses tumorigenicityIn vitro/animal(129)
Yu et al, 2023EvodiamineHIF1A histone lactylationProstate cancerImpairs HIF1A lactylationInhibits angiogenesis and PD-L1, induces ferroptosisIn vitro(130)
Li et al, 2025Ginsenoside Rk1PFKFB2-mediated glycolysisHepatic stellate cellsReduces aerobic glycolysis and lactate productionSuppresses EMTIn vitro(131)
Kumstel et al, 2022Therapeutic strategies: combination approachesCPI-613+lactate metabolism inhibitorsMitochondrial complex I + lactate metabolismPancreatic cancerLowers lactate poolsEnhanced anti-tumor activityAnimal model(132)
Zhang et al, 2025Biomimetic heavy-atom-free photosensitizerT cell and cancer cell metabolismTumor modelsReverses lactate-driven immunosuppressionBoosts photoimmunotherapyAnimal model(133)
Deng et al, 2024Bimetallic nanomodulator Sonodynamic-ferroptosis + lactate metabolismTumor modelsModulates lactate to reduce immunosuppressionReverses immunosuppressionAnimal model(134)
Li et al, 2026Dual-transformable MgGa-MOFLactate metabolism blockade + immune reactivationHepatocellular carcinomaBlocks lactate production and histone lactylationImmune reactivation and tumor suppressionAnimal model(135)
Chao et al, 2024Biomarker strategies: prognostic signaturesHigh H3K18 lactylation levelPrognostic indicatorEpithelial ovarian cancerElevated H3K18laCorrelates with poor prognosis and reduced platinum responseClinical (retrospective; prognostic + predictive of platinum response)(105)
Zhao et al, 2025Lactylation prognostic signature (DHCR7) Chemoresistance/immunotherapy modulatorBladder cancerIdentifies DHCR7 as lactylation-related modulatorPredicts chemoresistance and immunotherapy efficacyClinical (retrospective; prognostic + predictive of chemoresistance and immunotherapy efficacy)(106)
Yang et al, 2025Lactylation-related gene signaturePrognostic biomarkerRadiation-resistant NSCLC-Predicts prognosis and treatment responseClinical (retrospective; prognostic + predictive of treatment response)(107)
Hu et al, 2025Lactylation-related gene signatureChemotherapeutic efficacy predictionColorectal carcinoma-Prognostic for chemotherapeutic efficacyClinical (retrospective; predictive of chemotherapeutic efficacy)(108)
Cheng et al, 2023Lactylation-related gene signaturePrognostic biomarkerHepatocellular carcinoma-Predicts prognosis and treatment responsivenessClinical (retrospective; prognostic + predictive of treatment responsiveness)(136)
Xie et al, 2023CircXRN2 (Hippo pathway)Histone lactylation regulationBladder cancerSuppresses histone lactylation-driven progressionPredicts better outcomeClinical (retrospective; prognostic)(137)
Wu et al, 2023Histone lactylation-specific genes (NR6A1, OSBP2, UNC119B)Therapeutic targetsHepatocellular carcinomaIdentifies Kla-specific gene signaturesNovel therapeutic targetsClinical (retrospective; target discovery)(138)
Wu, 2023Protein lactylation profiling Diagnostic/prognostic markerHepatocellular carcinomaIn-depth lactylome analysisProvides prognostic informationClinical (retrospective; prognostic)(139)

[i] Prognostic=association with clinical outcome. Predictive=association with response to a specific treatment. Both=both types of evidence reported. This distinction applies only to clinical biomarker studies; preclinical cell and animal studies are not classified as prognostic or predictive. AARS1, alanyl-tRNA synthetase 1; AMPK, AMP-activated protein kinase; CaMKII, Ca2+/calmodulin-dependent protein kinase II; CAR-T, chimeric antigen receptor T-cell; CCR8, C-C motif chemokine receptor 8; CPI-613, a mitochondrial complex I inhibitor; DHCR7, 7-dehydrocholesterol reductase; DRP1, dynamin-related protein 1; EMT, epithelial-mesenchymal transition; GSH, glutathione; H3K9la, H3K14la, H3K18la, histone H3 lysine lactylation; HCC, hepatocellular carcinoma; HDAC, histone deacetylase; HIF1A, hypoxia-inducible factor 1-alpha; Kla, lysine lactylation; LDHA, lactate dehydrogenase A; LDHB, lactate dehydrogenase B; MCT1/4, monocarboxylate transporter 1/4; MgGa-MOF, magnesium-gallium metal-organic framework; MnSOD, manganese superoxide dismutase; MSN, mesoporous silica nanoparticle; NSCLC, non-small cell lung cancer; ODC1, ornithine decarboxylase 1; PD-L1, programmed death-ligand 1; PFKFB2, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2; PKM2, pyruvate kinase M2; ROS, reactive oxygen species; SIRT6, sirtuin 6.

Targeting lactate metabolism and transport

Disrupting lactate production and transport represents the most direct approach to modulate the lactylation landscape. The lactate dehydrogenase (LDH) family, particularly LDHA, catalyzes the final step of glycolysis converting pyruvate to lactate. Pharmacological inhibition of LDHA using small molecules such as FX11 (a small-molecule inhibitor of lactate dehydrogenase A) and oxamate has demonstrated efficacy in reducing histone lactylation and suppressing tumor progression (116,117). Mechanistically, oxamate enhances chimeric antigen receptor T-cell (CAR-T) therapy efficacy against glioblastoma by suppressing ectonucleotidases and C-C chemokine receptor type 8 (CCR8) lactylation, establishing that metabolic modulation can synergize with immunotherapy (117). Similarly, inhibition of LDHB suppresses the metastatic potential of lung cancer by reducing mitochondrial GSH catabolism, indicating isoform-specific therapeutic opportunities (118).

Monocarboxylate transporters (MCTs), particularly MCT1 and MCT4, mediate lactate export and import across cellular membranes. Pharmacological blockade of MCT1 using AZD3965 has shown promise in preclinical models. Importantly, MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies, demonstrating that lactate transport inhibition can enhance immunotherapeutic efficacy (119). In acute myeloid leukemia, targeting lactate metabolism by inhibiting MCT1 or MCT4 impairs leukemic cell proliferation and increases chemotherapeutic sensitivity (120). Combined targeting of LDH and MCTs is being explored, with synthetic catalysts working synergistically with MCT inhibitors to disrupt lactate metabolism (121). However, redundancy between MCT isoforms and potential metabolic adaptation mechanisms may limit monotherapy efficacy, suggesting that dual targeting strategies may be required for durable responses.

Pharmacological modulation of lactylation writers and erasers

Direct targeting of the enzymatic machinery that deposits or removes lactyl groups offers an alternative strategy. The identification of AARS1 and AARS2 as primary lactyltransferases has opened new therapeutic avenues (122,123). Small molecules that interfere with AARS1's lactate-sensing function or its lactyltransferase activity could potentially reduce global lactylation levels. Complementing this approach, inhibition of nuclear GTPSCS, which functions as a lactyl-CoA synthetase promoting histone lactylation and gliomagenesis, represents a compartment-specific targeting strategy (124). HBO1, identified as a histone lactyltransferase catalyzing H3K9la, may be targeted using existing acetyltransferase inhibitors, though selectivity remains a concern (116).

Targeting delactylases represents an equally valid approach, though context-dependent effects must be considered. Class I HDAC inhibitors (HDAC1-3) block both deacetylase and delactylase activities (125). SIRT6 inhibitors have been shown to reverse temozolomide resistance in glioblastoma by preventing H3K9 delactylation-mediated MGMT repression (126). The dual roles of these enzymes in regulating both acetylation and lactylation complicate therapeutic targeting, as global inhibition may produce unintended consequences on other PTM networks. Notably, the development of isoform-specific delactylase inhibitors that preferentially target lactylated substrates over acetylated ones represents an important future direction.

Natural products targeting the lactylation pathway

Natural products have emerged as a rich source of lactylation-modulating agents with favorable safety profiles. Demethylzeylasteral, a compound isolated from Tripterygium wilfordii, targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells (64,127). Mechanistically, this natural product reduces H3K18la levels at stemness gene promoters, decreasing CSC self-renewal capacity.

Other natural compounds have shown similar promise. Emodin regulates lactate metabolism by inhibiting MCT1 to delay non-small cell lung cancer progression (128). Royal jelly acid suppresses hepatocellular carcinoma tumorigenicity by inhibiting H3 histone lactylation at H3K9la and H3K14la sites (129). Evodiamine impairs HIF1A histone lactylation to inhibit semaphorin 3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer (130). Ginsenoside Rk1 suppresses epithelial-mesenchymal transition of hepatic stellate cells via PFKFB2-mediated aerobic glycolysis (131). A critical comparative analysis reveals that most natural products indirectly modulate lactylation by reducing glycolytic flux or lactate production rather than directly targeting the lactylation machinery. Whether this indirect mechanism provides superior therapeutic windows compared with direct enzymatic inhibition remains to be determined.

Rational combination therapeutic strategies

Given that lactylation-driven resistance involves multiple interconnected pathways, combination strategies may offer the greatest therapeutic promise. Co-targeting lactate metabolism with conventional chemotherapy has shown synergistic effects. Simultaneous inhibition of ornithine decarboxylase 1 and pyruvate kinase M2 exerts synergistic effects against hepatocellular carcinoma cells, suggesting that multi-node metabolic targeting may be more effective than single-agent approaches (125). In pancreatic cancer, combinatorial treatment with CPI-613 (a mitochondrial complex I inhibitor) and inhibitors of lactate metabolism shows enhanced anti-tumor activity (132).

The combination of lactylation-targeting agents with immunotherapy represents a particularly attractive strategy. As discussed in the 'Immunotherapy resistance' section, lactylation promotes PD-L1 expression and immunosuppressive microenvironment formation. Therefore, combining lactate metabolism inhibitors with immune checkpoint blockade may overcome immunotherapy resistance. A biomimetic heavy-atom-free photosensitizer-based combination therapy simultaneously reverses T lymphocyte and cancer cell metabolism to boost photoimmunotherapy (133). Similarly, a bimetallic nanomodulator reverses immunosuppression via sonodynamic-ferroptosis and lactate metabolism modulation (134). A dual-transformable MgGa-males absent on the first nanoplatform for HCC therapy operates via lactate metabolism blockade and immune reactivation (135). Notably, the success of these combination approaches may depend on careful sequencing, as metabolic perturbations may temporarily impair T cell function before enhancing anti-tumor immunity. Most combination data remain preclinical and use heterogeneous schedules. Evidence that lactylation targeting improves survival in patient-derived or immunocompetent models without impairing normal lactate-dependent tissues is still limited (132-135).

Lactylation-based biomarkers for patient stratification

The clinical translation of lactylation-targeted therapies requires robust biomarkers to identify patients most likely to benefit. Multiple studies have developed lactylation-related gene signatures that have been associated with prognosis and treatment response across cancer types in retrospective cohorts. In hepatocellular carcinoma, lactylation-related gene signatures have been associated with prognosis and treatment responsiveness (136). In lung adenocarcinoma, lactylation-related gene signatures have been associated with prognosis and treatment response in radiation-resistant NSCLC (107,137). In colorectal cancer, integrative machine learning identifies lactylation-related gene signatures reported to be prognostic for chemotherapeutic efficacy (108,129).

Specific lactylation marks have been reported as prognostic indicators, although independent validation remains limited. High histone H3K18 lactylation levels have been associated with poor prognosis in epithelial ovarian cancer and with reduced response to platinum-based chemotherapy in retrospective cohorts (105,138). Lactylation prognostic signatures have been proposed for bladder cancer, identifying DHCR7 as a modulator of chemoresistance and immunotherapy efficacy (106,139). For glioblastoma, lactylation-associated gene signatures have been associated with stratification by temozolomide response and with survival outcomes in retrospective analyses (84). A critical limitation of current signature-based approaches is the lack of standardization across platforms and cancer types. Most signatures are constructed from bulk RNA-seq data and infer lactylation from gene expression rather than measuring the modification itself (84,105,106,108). They are largely retrospective, lack independent external validation and have not been compared with established clinical markers; their predictive value therefore remains uncertain. Prospective validation in clinical trial cohorts and development of clinically deployable assays (such as immunohistochemistry for specific lactylation marks) will be essential before these biomarkers can guide treatment decisions. Until then, lactylation-based signatures should be regarded as hypothesis-generating rather than clinically actionable. The integration of lactylation markers with existing clinical and molecular parameters may ultimately enable precision targeting of this metabolic-epigenetic axis.

Challenges, unresolved questions and future perspectives

Despite substantial progress in understanding lactylation-driven cancer stemness and drug resistance, several critical challenges and unresolved questions remain that warrant careful consideration. A fundamental technical limitation concerns the distinction between enzymatic and non-enzymatic lactylation in cancer cells. Although Zhang et al (22) provided evidence for non-enzymatic lysine lactylation under high-lactate conditions, the relative contribution of AARS1/2-mediated vs. non-enzymatic lactylation to the global lactylome in the context of cancer stem cell maintenance has not been systematically quantified. Bao et al (34) performed subcellular proteomic mapping of lysine lactylation, revealing distinct compartmentalization patterns, yet whether enzymatic and non-enzymatic mechanisms exhibit different subcellular preferences remains unexplored. This distinction carries therapeutic implications, as targeting AARS1 may not fully abrogate lactylation driven by extreme metabolic stress (16). A major limitation is that many studies infer lactylation from pan-Kla immunoblotting or global lactylome data without site-specific validation, chiral resolution, or rescue experiments (14,15,22,34,140). Consequently, some reported associations may reflect general metabolic stress rather than a defined lactylation-dependent mechanism.

Another pressing unresolved question concerns the identity and specificity of lactylation reader proteins. Zhai et al (32) identified DPF2 as a histone lactylation reader that drives transcription and tumorigenesis, while Nuñez et al (31) characterized TRIM33 bromodomain recognition of histone lactylation with selectivity distinct from acetylation recognition. However, systematic identification of readers remains incomplete compared with the well-established acetylation reader repertoire and whether distinct readers recognize different lactylation marks (such as H3K9la vs. H3K18la) or whether lactylation-specific readers exist beyond bromodomain-containing proteins remains unknown. The development of lactylation-specific antibodies and affinity purification strategies may be essential to address this gap.

The functional interplay between lactylation and other post-translational modifications represents an area requiring deeper mechanistic investigation. Chen et al (109,141) revealed that MRE11 lactylation at lysine 673 promotes homologous recombination repair, while acetylation at the same residue exerts distinct regulatory effects on DNA end resection, demonstrating functional divergence between these modifications at identical sites. However, compared with the well-characterized crosstalk between acetylation and other acyl modifications, systematic investigation of lactylation-acetylation interplay at the same lysine residue remains limited. Lao et al (114) deciphered multiple PTM-associated regulatory patterns in hepatocellular carcinoma, but integrative frameworks that predict context-dependent PTM crosstalk are lacking.

Translational barriers for lactylation-targeted therapies are substantial. Although natural products such as demethylzeylasteral (64,127,142) has shown preclinical efficacy in suppressing cancer stemness by inhibiting histone lactylation, the selectivity of these agents for malignant vs. normal tissues remains concerning given the essential role of lactate metabolism in physiological processes. Li et al (69) performed single-cell transcriptome analysis revealing the association between histone lactylation and cisplatin resistance in bladder cancer, yet whether lactylation signatures can reliably stratify patients for therapy remains to be validated in prospective clinical cohorts. Furthermore, the development of isoform-specific delactylase inhibitors that preferentially target lactylated substrates over acetylated ones represents an urgent priority, as current HDAC inhibitors broadly block both deacetylase and delactylase activities (24,143).

Emerging research directions offer promising opportunities to overcome these challenges. The integration of single-cell and spatial transcriptomics, as exemplified by Yu et al (67) in hepatocellular carcinoma, enables elucidation of how stromal cells regulate histone lactylation to promote tumor progression. Such approaches will facilitate precise mapping of lactylation heterogeneity within the tumor microenvironment and cancer stem cell niches. Advances in genetic code expansion technology reported by Shao et al (140) enable site-specific lactylation in living cells, providing powerful tools to dissect causal roles of individual lactylation sites in stemness regulation. Lastly, machine learning approaches for predicting lactylation sites and readers may accelerate discovery of context-specific regulatory mechanisms (144). Addressing these challenges through coordinated efforts in chemical biology, structural biology, and clinical translation may ultimately determine whether targeting the lactylation landscape can be successfully translated into therapeutic strategies for overcoming cancer stemness and drug resistance.

Conclusions

Lysine lactylation serves as a central metabolic-epigenetic hub that integrates Warburg-effect-derived lactate signals to sustain cancer stem cell self-renewal, foster multidrug resistance and remodel an immunosuppressive tumor microenvironment. The writer and eraser machinery (AARS1/2, HBO1, KAT8, KAT2A, HDAC1-3, SIRT3, SIRT6) and several lactylation marks (H3K9la, H3K18la, H3K14la) are well supported, whereas enzymatic vs. non-enzymatic deposition, reader identity and spatial heterogeneity remain preliminary. The principal gap is the absence of site-selective modulators discriminating lactylation from other acylations. Future work must validate causal mechanisms at defined sites, develop selective inhibitors, and prospectively validate lactylation-based biomarkers with standardized assays before clinical translation.

Availability of data and materials

Not applicable.

Authors' contributions

YY and NZ contributed equally to conceptualization, literature review and drafting the original manuscript. DW and DY performed literature searching and figure preparation. YZ and XL critically revised the manuscript for important intellectual content and gave final approval. Data authentication is not applicable. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations:

AARS1/2

alanyl-tRNA synthetase 1/2

ANTXR1

anthrax toxin receptor 1

BRAF

B-Raf proto-oncogene

CAF

cancer-associated fibroblast

CAR-T

chimeric antigen receptor T-cell

CCR8

C-C chemokine receptor type 8

cGAS

cyclic GMP-AMP synthase

CSC

cancer stem cell

DHCR7

7-dehydrocholesterol reductase

DPF2

double PHD fingers 2

eEF1A2

eukaryotic translation elongation factor 1 alpha 2

EGFR

epidermal growth factor receptor

EMT

epithelial-mesenchymal transition

ENO1

enolase 1

ERK

extracellular signal-regulated kinase

FX11

a small-molecule inhibitor of lactate dehydrogenase A

GCLC

glutamate-cysteine ligase catalytic subunit

GCN5

general control non-derepressible 5

GSC

glioblastoma stem cell

GTPSCS

GTP-specific succinyl-CoA synthetase

H3K9la

histone H3 lysine 9 lactylation

H3K14la

histone H3 lysine 14 lactylation

H3K18la

histone H3 lysine 18 lactylation

H4K12la

histone H4 lysine 12 lactylation

HBO1

histone acetyltransferase binding to ORC1

HCC

hepatocellular carcinoma

HDAC

histone deacetylase

HIF1α

hypoxia-inducible factor 1-alpha

IGF2

insulin-like growth factor 2

JNK

c-Jun N-terminal kinase

KAT2A

lysine acetyltransferase 2A

KAT8

lysine acetyltransferase 8

Kla

lysine lactylation

KRAS

Kirsten rat sarcoma viral oncogene homolog

LDH

lactate dehydrogenase

LINC01127

long intergenic non-protein coding RNA 1127

LSD1

lysine-specific demethylase 1

MAP4K4

mitogen-activated protein kinase kinase kinase kinase 4

MCM7

minichromosome maintenance complex component 7

MCT

monocarboxylate transporter

METTL3

methyltransferase-like 3

MGMT

O6-methylguanine-DNA methyltransferase

MOESIN

membrane-organizing extension spike protein

m6A

N6-methyladenosine

MRE11

meiotic recombination 11 homolog

MVP

major vault protein

NNMT

nicotinamide N-methyltransferase

NSCLC

non-small cell lung cancer

PCBP2

poly(rC)-binding protein 2

PD-1

programmed cell death protein 1

PD-L1

programmed death-ligand 1

PFKFB2

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2

POLR2A

RNA polymerase II subunit A

PRMT1

protein arginine methyltransferase 1

PSMD14

proteasome 26S subunit, non-ATPase 14

PTBP1

polypyrimidine tract-binding protein 1

PTEN

phosphatase and tensin homolog

PTM

post-translational modification

SHMT2

serine hydroxymethyltransferase 2

SIRT3

sirtuin 3

SIRT4

sirtuin 4

SIRT6

sirtuin 6

SOX9

SRY-box transcription factor 9

TME

tumor microenvironment

TMZ

temozolomide

TKI

tyrosine kinase inhibitor

TRIM33

tripartite motif-containing protein 33

Wnt

wingless-related integration site

YBX1

Y-box binding protein 1

YTHDF2

YTH N6-methyladenosine RNA binding protein 2

ZMIZ1

zinc finger MIZ-type containing 1

Acknowledgements

Not applicable.

Funding

No funding was received.

References

1 

Duval AJ, Seker-Polat F, Rogozinska M, Kinali M, Walts AE, Neyisci O, Zhang Y, Li Z, Tanner EJ III, Grubbs AE, et al: SOX9 drives a stem-like transcriptional state and platinum resistance in high-grade serous ovarian cancer. J Clin Invest. 135:e1864672025. View Article : Google Scholar : PubMed/NCBI

2 

Hubert CG, Stauffer SR and Lathia JD: A TOX-ic axis of epigenetic stem cell maintenance and chemoresistance in colon cancer. PLoS Biol. 21:e30022952023. View Article : Google Scholar : PubMed/NCBI

3 

Li F, Si W, Xia L, Yin D, Wei T, Tao M, Cui X, Yang J, Hong T and Wei R: Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. Mol Cancer. 23:902024. View Article : Google Scholar : PubMed/NCBI

4 

Yang J and Yu X, Xiao M, Xu H, Tan Z, Lei Y, Guo Y, Wang W, Xu J, Shi S and Yu X: Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer. Gut. 74:1859–1872. 2025. View Article : Google Scholar : PubMed/NCBI

5 

Yang Z, Yan C, Ma J, Peng P, Ren X, Cai S, Shen X, Wu Y, Zhang S, Wang X, et al: Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. Nat Metab. 5:61–79. 2023. View Article : Google Scholar : PubMed/NCBI

6 

Liu R, Ren X, Park YE, Feng H, Sheng X, Song X, AminiTabrizi R, Shah H, Li L, Zhang Y, et al: Nuclear GTPSCS functions as a lactyl-CoA synthetase to promote histone lactylation and gliomagenesis. Cell Metab. 37:377–394.e9. 2025. View Article : Google Scholar

7 

Sun P, Ma L and Lu Z: Lactylation: Linking the Warburg effect to DNA damage repair. Cell Metab. 36:1637–1639. 2024. View Article : Google Scholar : PubMed/NCBI

8 

Feng F, Wu J, Chi Q, Wang S, Liu W, Yang L, Song G, Pan L, Xu K and Wang C: Lactylome analysis unveils lactylation-dependent mechanisms of stemness remodeling in the liver cancer stem cells. Adv Sci (Weinh). 11:e24059752024. View Article : Google Scholar : PubMed/NCBI

9 

Lv M, Yang X, Xu C, Song Q, Zhao H, Sun T, Liu J, Zhang Y, Sun G, Xue Y and Zhang Z: SIRT4 promotes pancreatic cancer stemness by enhancing histone lactylation and epigenetic reprogramming stimulated by calcium signaling. Adv Sci (Weinh). 12:e24125532025. View Article : Google Scholar : PubMed/NCBI

10 

Gan L, Sui Q, Xu MD, Yang F, Li M, Yuan Y, Lin Y, Zhang X, Bi G, Jiang W, et al: A tumor-derived lactate/ENO1 lactylation feedback loop facilitates osimertinib resistance of lung adenocarcinoma. Drug Resist Updat. 85:1013462026. View Article : Google Scholar : PubMed/NCBI

11 

Zhao X, Li M, Fu Y, Chen C, Chen Y, Xu L, Bao L, Ma Z, Xu J, Zhou S, et al: PSMD14-mediated PFKFB2 deubiquitination activates H3K27 lactylation to drive cancer stemness in gastric adenocarcinoma. Cell Death Differ. 33:813–830. 2026. View Article : Google Scholar

12 

Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, Liu W, Kim S, Lee S, Perez-Neut M, et al: Metabolic regulation of gene expression by histone lactylation. Nature. 574:575–580. 2019. View Article : Google Scholar : PubMed/NCBI

13 

Liberti MV and Locasale JW: Histone lactylation: A new role for glucose metabolism. Trends Biochem Sci. 45:179–182. 2020. View Article : Google Scholar : PubMed/NCBI

14 

Zhang D, Gao J, Zhu Z, Mao Q, Xu Z, Singh PK, Rimayi CC, Moreno-Yruela C, Xu S, Li G, et al: Lysine L-lactylation is the dominant lactylation isomer induced by glycolysis. Nat Chem Biol. 21:91–99. 2025. View Article : Google Scholar

15 

Moreno-Yruela C, Bæk M, Monda F and Olsen CA: Chiral post-translational modification to lysine ε-Amino Groups. Acc Chem Res. 55:1456–1466. 2022. View Article : Google Scholar : PubMed/NCBI

16 

Zong Z, Xie F, Wang S, Wu X, Zhang Z, Yang B and Zhou F: Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis. Cell. 187:2375–2392.e33. 2024. View Article : Google Scholar : PubMed/NCBI

17 

Ju J, Zhang H, Lin M, Yan Z, An L, Cao Z, Geng D, Yue J, Tang Y, Tian L, et al: The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer. J Clin Invest. 134:e1745872024. View Article : Google Scholar : PubMed/NCBI

18 

Li H, Liu C, Li R, Zhou L, Ran Y, Yang Q, Huang H, Lu H, Song H, Yang B, et al: AARS1 and AARS2 sense L-lactate to regulate cGAS as global lysine lactyltransferases. Nature. 634:1229–1237. 2024. View Article : Google Scholar : PubMed/NCBI

19 

Niu Z, Chen C, Wang S, Lu C, Wu Z, Wang A, Mo J, Zhang J, Han Y, Yuan Y, et al: HBO1 catalyzes lysine lactylation and mediates histone H3K9la to regulate gene transcription. Nat Commun. 15:35612024. View Article : Google Scholar : PubMed/NCBI

20 

Xie B, Zhang M, Li J, Cui J, Zhang P, Liu F, Wu Y, Deng W, Ma J, Li X, et al: KAT8-catalyzed lactylation promotes eEF1A2-mediated protein synthesis and colorectal carcinogenesis. Proc Natl Acad Sci USA. 121:e23141281212024. View Article : Google Scholar : PubMed/NCBI

21 

Zhu R, Ye X, Lu X, Xiao L, Yuan M, Zhao H, Guo D, Meng Y, Han H, Luo S, et al: ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. Cell Metab. 37:361–376.e7. 2025. View Article : Google Scholar

22 

Zhang C, Zhou T, Li C, Wang D, Tao J, Zhu X, Lu J, Ni J and Yao YF: Deciphering novel enzymatic and non-enzymatic lysine lactylation in Salmonella. Emerg Microbes Infect. 14:24758382025. View Article : Google Scholar : PubMed/NCBI

23 

Moreno-Yruela C, Zhang D, Wei W, Bæk M, Liu W, Gao J, Danková D, Nielsen AL, Bolding JE, Yang L, et al: Class I histone deacetylases (HDAC1-3) are histone lysine delactylases. Sci Adv. 8:eabi66962022. View Article : Google Scholar : PubMed/NCBI

24 

Gonzatti MB, Hintzen JCJ, Sharma I, Najar MA, Tsusaka T, Marcinkiewicz MM, Da Silva Crispim CV, Snyder NW, Burslem GM and Goldberg EL: Class I histone deacetylases catalyze lysine lactylation. J Biol Chem. 301:1106022025. View Article : Google Scholar : PubMed/NCBI

25 

Tsusaka T, Najar MA, Sharma I, Marcinkiewicz MM, Crispim CVDS, Snyder NW, Burslem GM and Goldberg EL: Class I histone deacetylases catalyze lysine lactylation. bioRxiv [Preprint]. 2025.02.25.640220. 2025.

26 

Nickel GA, Pederson NJ, Faheem, Yang Z, Bulf J and Diehl KL: Sirtuin 6 is a histone delactylase. J Biol Chem. 301:1107952025. View Article : Google Scholar : PubMed/NCBI

27 

Chen C, Zhang Y, Zang Y, Fan Z, Han Y, Bai X, Wang A, Zhang J, Wang J and Zhang K: SIRT3 functions as an eraser of histone H3K9 lactylation to modulate transcription for inhibiting the progression of esophageal cancer. Mol Cell Proteomics. 24:1009732025. View Article : Google Scholar : PubMed/NCBI

28 

Zou L, Liu Z, Peng L, Wu B, Huang Y, Wen X, Han D, Tan W and Zhou Y: Delactylation of H3K9 by Sirtuin6 inhibits MGMT transcription and reverses temozolomide resistance in glioblastoma. Int J Biol Macromol. 327:1473322025. View Article : Google Scholar : PubMed/NCBI

29 

Jin J, Bai L, Wang D, Ding W, Cao Z, Yan P, Li Y, Xi L, Wang Y, Zheng X, et al: SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth. EMBO Rep. 24:e560522023. View Article : Google Scholar : PubMed/NCBI

30 

He X, Li Y, Li J, Li Y, Chen S, Yan X, Xie Z, Du J, Chen G, Song J and Mei Q: HDAC2-mediated METTL3 delactylation promotes DNA damage repair and chemotherapy resistance in triple-negative breast cancer. Adv Sci (Weinh). 12:e24131212025. View Article : Google Scholar : PubMed/NCBI

31 

Nuñez R, Sidlowski PFW, Steen EA, Wynia-Smith SL, Sprague DJ, Keyes RF and Smith BC: The TRIM33 bromodomain recognizes histone lysine lactylation. ACS Chem Biol. 19:2418–2428. 2024. View Article : Google Scholar : PubMed/NCBI

32 

Zhai G, Niu Z, Jiang Z, Zhao F, Wang S, Chen C, Zheng W, Wang A, Zang Y, Han Y and Zhang K: DPF2 reads histone lactylation to drive transcription and tumorigenesis. Proc Natl Acad Sci USA. 121:e24214961212024. View Article : Google Scholar : PubMed/NCBI

33 

Wei E, Ji D, Jia Y, Sun Z, Gao C, Zeng C, Wang C, Yu M, Shang G, Xie L, et al: BRD9 recognizes lactate-induced H3K18 lactylation to drive oncogenic chromatin remodeling in hepatocellular carcinoma. Cell Death Differ. 33:1946–1959. 2026. View Article : Google Scholar : PubMed/NCBI

34 

Bao Q, Wan N, He Z, Cao J, Yuan W, Hao H and Ye H: Subcellular proteomic mapping of lysine lactylation. J Am Soc Mass Spectrom. 35:3221–3232. 2024. View Article : Google Scholar : PubMed/NCBI

35 

He Y, Ji Z, Gong Y, Fan L, Xu P, Chen X, Miao J, Zhang K, Zhang W, Ma P, et al: Numb/Parkin-directed mitochondrial fitness governs cancer cell fate via metabolic regulation of histone lactylation. Cell Rep. 42:1120332023. View Article : Google Scholar : PubMed/NCBI

36 

Mao Y, Zhang J, Zhou Q, He X, Zheng Z, Wei Y, Zhou K, Lin Y, Yu H, Zhang H, et al: Hypoxia induces mitochondrial protein lactylation to limit oxidative phosphorylation. Cell Res. 34:13–30. 2024. View Article : Google Scholar : PubMed/NCBI

37 

Huang B, Jin M, Cui G, Wang Z, Wang F, Chen M, Zhu L, Li Y, Yang X, Li R, et al: GCN5-ERK lactylation-phosphorylation loop amplifies lactate-driven cancer progression. Nat Chem Biol. 22:634–648. 2026. View Article : Google Scholar : PubMed/NCBI

38 

Sun S, Xu Z, He L, Shen Y, Yan Y, Lv X, Zhu X, Li W, Tian WY, Zheng Y, et al: Metabolic regulation of cytoskeleton functions by HDAC6-catalyzed α-tubulin lactylation. Nat Commun. 15:83772024. View Article : Google Scholar

39 

Zhou J, Qiu S, Yang X, Wu Y, Yao X, Hu H, Luo J, Wijaya CS, Ma L, Long X, et al: Hypoxia-Induced PRMT1 lactylation drives vimentin arginine asymmetric dimethylation in tumor metastasis. Adv Sci (Weinh). 12:e098612025. View Article : Google Scholar : PubMed/NCBI

40 

Jiang J, Huang D, Jiang Y, Hou J, Tian M, Li J, Sun L, Zhang Y, Zhang T, Li Z, et al: Lactate modulates cellular metabolism through histone lactylation-mediated gene expression in non-small cell lung cancer. Front Oncol. 11:6475592021. View Article : Google Scholar : PubMed/NCBI

41 

Sharma NK and Pal JK: Metabolic ink lactate modulates epigenomic landscape: A concerted role of pro-tumor microenvironment and macroenvironment during carcinogenesis. Curr Mol Med. 21:177–181. 2021. View Article : Google Scholar

42 

Gu J, Zhou J, Chen Q, Xu X, Gao J, Li X, Shao Q, Zhou B, Zhou H, Wei S, et al: Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells. Cell Rep. 39:1109862022. View Article : Google Scholar

43 

Yang D, Yin J, Shan L, Yi X, Zhang W and Ding Y: Identification of lysine-lactylated substrates in gastric cancer cells. iScience. 25:1046302022. View Article : Google Scholar : PubMed/NCBI

44 

Hong H, Chen X, Wang H, Gu X, Yuan Y and Zhang Z: Global profiling of protein lysine lactylation and potential target modified protein analysis in hepatocellular carcinoma. Proteomics. 23:e22004322023. View Article : Google Scholar : PubMed/NCBI

45 

Huang Y, Luo G, Peng K, Song Y, Wang Y, Zhang H, Li J, Qiu X, Pu M, Liu X, et al: Lactylation stabilizes TFEB to elevate autophagy and lysosomal activity. J Cell Biol. 223:e2023080992024. View Article : Google Scholar : PubMed/NCBI

46 

Jing F, Zhu L, Zhang J, Zhou X, Bai J, Li X, Zhang H and Li T: Multi-omics reveals lactylation-driven regulatory mechanisms promoting tumor progression in oral squamous cell carcinoma. Genome Biol. 25:2722024. View Article : Google Scholar : PubMed/NCBI

47 

Meng Q, Sun H, Zhang Y, Yang X, Hao S, Liu B, Zhou H, Xu ZX and Wang Y: Lactylation stabilizes DCBLD1 activating the pentose phosphate pathway to promote cervical cancer progression. J Exp Clin Cancer Res. 43:362024. View Article : Google Scholar : PubMed/NCBI

48 

Luo Y, Yang Z, Yu Y and Zhang P: HIF1α lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer. Int J Biol Macromol. 222:2225–2243. 2022. View Article : Google Scholar : PubMed/NCBI

49 

Yang J, Luo L, Zhao C, Li X, Wang Z, Zeng Z, Yang X, Zheng X, Jie H, Kang L, et al: A positive feedback loop between inactive VHL-Triggered histone lactylation and PDGFRβ signaling drives clear cell renal cell carcinoma progression. Int J Biol Sci. 18:3470–3483. 2022. View Article : Google Scholar

50 

Wang X, Ying T, Yuan J, Wang Y, Su X, Chen S, Zhao Y, Zhao Y, Sheng J, Teng L, et al: BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation. Endocr Relat Cancer. 30:e2203442023. View Article : Google Scholar : PubMed/NCBI

51 

Zhang C, Yu R, Li S, Yuan M, Hu T, Liu J, Ke H, Ye S, Yun J, Huang J, et al: KRAS mutation increases histone H3 lysine 9 lactylation (H3K9la) to promote colorectal cancer progression by facilitating cholesterol transporter GRAMD1A expression. Cell Death Differ. 32:2225–2238. 2025. View Article : Google Scholar : PubMed/NCBI

52 

Gao J, Liu R, Huang K, Li Z, Sheng X, Chakraborty K, Han C, Zhang D, Becker L and Zhao Y: Dynamic investigation of hypoxia-induced L-lactylation. Proc Natl Acad Sci USA. 122:e24048991222025. View Article : Google Scholar : PubMed/NCBI

53 

Zang Y, Wang A, Zhang J, Xia M, Jiang Z, Jia B, Lu C, Chen C, Wang S, Zhang Y, et al: Hypoxia promotes histone H3K9 lactylation to enhance LAMC2 transcription in esophageal squamous cell carcinoma. iScience. 27:1101882024. View Article : Google Scholar : PubMed/NCBI

54 

Miao Z, Zhao X and Liu X: Hypoxia induced β-catenin lactylation promotes the cell proliferation and stemness of colorectal cancer through the wnt signaling pathway. Exp Cell Res. 422:1134392023. View Article : Google Scholar

55 

Xiong J, He J, Zhu J, Pan J, Liao W, Ye H, Wang H, Song Y, Du Y, Cui B, et al: Lactylation-driven METTL3-mediated RNA m(6)A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. 82:1660–1677.e10. 2022. View Article : Google Scholar : PubMed/NCBI

56 

Cai J, Zhang P, Cai Y, Zhu G, Chen S, Song L, Du J, Wang B, Dai W, Zhou J, et al: Lactylation-Driven NUPR1 Promotes Immunosuppression of Tumor-Infiltrating Macrophages in Hepatocellular Carcinoma. Adv Sci (Weinh). 12:e24130952025. View Article : Google Scholar : PubMed/NCBI

57 

Huang ZW, Zhang XN, Zhang L, Liu LL, Zhang JW, Sun YX, Xu JQ, Liu Q and Long ZJ: STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct Target Ther. 8:3912023. View Article : Google Scholar : PubMed/NCBI

58 

De Leo A, Ugolini A, Yu X, Scirocchi F, Scocozza D, Peixoto B, Pace A, D'Angelo L, Liu JKC, Etame AB, et al: Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity. 57:1105–1123.e8. 2024. View Article : Google Scholar : PubMed/NCBI

59 

Li Z, Liang P, Chen Z, Chen Z, Jin T, He F, Chen X and Yang K: CAF-secreted LOX promotes PD-L1 expression via histone Lactylation and regulates tumor EMT through TGFβ/IGF1 signaling in gastric cancer. Cell Signal. 124:1114622024. View Article : Google Scholar

60 

Kong W, He J, Zhou Q, Zhou X, Wei X, Yang Y, Mei Y, Wang S, Zhang X, Yao B, et al: Histone lactylation-related genes correlate with the molecular patterns and functions of cancer-associated fibroblasts and have significant clinical implications in clear cell renal cell carcinoma. Heliyon. 10:e335542024. View Article : Google Scholar : PubMed/NCBI

61 

He J, Li W, Wang S, Lan J, Hong X, Liao L, Kang D, Wang W, Wang R, Zhang W, et al: Cancer associated fibroblasts-derived lactate induces oxaliplatin treatment resistance by promoting cancer stemness via ANTXR1 lactylation in colorectal cancer. Cancer Lett. 631:2179172025. View Article : Google Scholar : PubMed/NCBI

62 

Zhang C, Zhou W, Xu H, Xu J, Li J, Liu X, Lu X, Dai J, Jiang Y, Wang W, et al: Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop. Oncogene. 44:1400–1414. 2025. View Article : Google Scholar : PubMed/NCBI

63 

Li L, Li Z, Meng X, Wang X, Song D, Liu Y, Xu T, Qin J, Sun N, Tian K, et al: Histone lactylation-derived LINC01127 promotes the self-renewal of glioblastoma stem cells via the cis-regulating the MAP4K4 to activate JNK pathway. Cancer Lett. 579:2164672023. View Article : Google Scholar : PubMed/NCBI

64 

Pan L, Feng F, Wu J, Fan S, Han J, Wang S, Yang L, Liu W, Wang C and Xu K: Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res. 181:1062702022. View Article : Google Scholar : PubMed/NCBI

65 

Zhang X, Li Y and Chen Y: Development of a comprehensive gene signature linking hypoxia, glycolysis, lactylation, and metabolomic insights in gastric cancer through the integration of bulk and single-cell RNA-Seq data. Biomedicines. 11:29482023. View Article : Google Scholar : PubMed/NCBI

66 

Lu X, Zhou Z, Qiu P and Xin T: Integrated single-cell and bulk RNA-sequencing data reveal molecular subtypes based on lactylation-related genes and prognosis and therapeutic response in glioma. Heliyon. 10:e307262024. View Article : Google Scholar : PubMed/NCBI

67 

Yu Y, Li Y, Zhou L, Cheng X and Gong Z: Hepatic stellate cells promote hepatocellular carcinoma development by regulating histone lactylation: Novel insights from single-cell RNA sequencing and spatial transcriptomics analyses. Cancer Lett. 604:2172432024. View Article : Google Scholar : PubMed/NCBI

68 

Han R, Chi G, Sun D, Xu Z, Zhou L and Xu K: Single-cell and spatial transcriptomics reveal lactylation-associated tumor cell clusters and define a prognostic risk model in glioblastoma. BMC Cancer. 25:19012025. View Article : Google Scholar : PubMed/NCBI

69 

Li F, Zhang H, Huang Y, Li D, Zheng Z, Xie K, Cao C, Wang Q, Zhao X, Huang Z, et al: Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat. 73:1010592024. View Article : Google Scholar : PubMed/NCBI

70 

Li J, Tang C, Zhang X, Xing R and Guo Q: Histone Lactylation-Driven Upregulation of VRK1 Expression Promotes Stemness and Proliferation of Glioma Stem Cells. Adv Sci (Weinh). 12:e038972025. View Article : Google Scholar : PubMed/NCBI

71 

Liu Z, Han J, Su S, Zeng Q, Wu Z, Yuan J and Yang J: Histone lactylation facilitates MCM7 expression to maintain stemness and radio-resistance in hepatocellular carcinoma. Biochem Pharmacol. 236:1168872025. View Article : Google Scholar : PubMed/NCBI

72 

Zhang Q, Han Z, Liu JH, Li M, Li W, Zhou X and Liu X: Hypoxia facilitates stemness of colon cancer cells via histone lactylation. Biochim Biophys Acta Mol Basis Dis. 1871:1679932025. View Article : Google Scholar : PubMed/NCBI

73 

Nguyen NTB, Gevers S, Kok RNU, Burgering LM, Neikes H, Akkerman N, Betjes MA, Ludikhuize MC, Gulersonmez C, Stigter ECA, et al: Lactate controls cancer stemness and plasticity through epigenetic regulation. Cell Metab. 37:903–919.e10. 2025. View Article : Google Scholar : PubMed/NCBI

74 

Qiao Z, Li Y, Li S, Liu S and Cheng Y: Hypoxia-induced SHMT2 protein lactylation facilitates glycolysis and stemness of esophageal cancer cells. Mol Cell Biochem. 479:3063–3076. 2024. View Article : Google Scholar : PubMed/NCBI

75 

Li Q, Lin G, Zhang K, Liu X, Li Z, Bing X, Nie Z, Jin S, Guo J and Min X: Hypoxia exposure induces lactylation of Axin1 protein to promote glycolysis of esophageal carcinoma cells. Biochem Pharmacol. 226:1164152024. View Article : Google Scholar : PubMed/NCBI

76 

Yan F, Teng Y, Li X, Zhong Y, Li C, Yan F and He X: Hypoxia promotes non-small cell lung cancer cell stemness, migration, and invasion via promoting glycolysis by lactylation of SOX9. Cancer Biol Ther. 25:23041612024. View Article : Google Scholar : PubMed/NCBI

77 

Zhao S, Cheng J, Zhou G, Tao L, Xing J, Liu L, Chen Z and Song P: Histone lactylation-driven YTHDF2 promotes non-small cell lung cancer cell glycolysis and stemness by recognizing m6A modification of SFRP2. Biochem Pharmacol. 240:1170972025. View Article : Google Scholar : PubMed/NCBI

78 

Yuan Q, Zhang H, Zhang N, Qian Y, Hong Z, Wan X, Ye R, Chen D, Feng X, Yu G and Niu M: BPHL promotes TNBC stemness by resolving R-loops via POLR2A lactylation inhibition and BARD1-mediated ubiquitination. Cancer Lett. 645:2183882026. View Article : Google Scholar : PubMed/NCBI

79 

Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, Nativi C, Richichi B, Scozzafava A, Carta F, et al: Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle. 12:1791–1801. 2013. View Article : Google Scholar : PubMed/NCBI

80 

Chen S, Huang G, Guo Z, Guo Z, Cao C, Zhao G, Lubamba GP, Huang Y, Yang J, Lian H, et al: Tumor-associated Schwann cells promote salivary adenoid cystic carcinoma stem-like reprogramming via IGF2/IGF1R induced histone H3 lysine 18 lactylation. Cancer Lett. 628:2178472025. View Article : Google Scholar : PubMed/NCBI

81 

Shi L, Li B, Tan J, Zhu L, Zhang S, Zhang Y, Xiang M, Li J, Chen Y, Han X, et al: Exosomal lncRNA Mir100hg from lung cancer stem cells activates H3K14 lactylation to enhance metastatic activity in non-stem lung cancer cells. J Nanobiotechnology. 23:1562025. View Article : Google Scholar : PubMed/NCBI

82 

Wang D, Du G, Chen X, Wang J, Liu K, Zhao H, Cheng C, He Y, Jing N, Xu P, et al: Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer. Cell Death Differ. 31:779–791. 2024. View Article : Google Scholar : PubMed/NCBI

83 

Zhou Z, Yin X, Sun H, Lu J, Li Y, Fan Y, Lv P, Han M, Wu J, Li S, et al: PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis. Cancer Res. 85:739–757. 2025. View Article : Google Scholar

84 

Tang X, Liu Y, Yang C, Zhang H, Zhang G, Wang Q, Jiang S, Gao X, Liu Y and Dong Y: Deciphering the lactylation landscape in glioma: a novel gene signature predicts patient survival and immunotherapy sensitivity. Front Immunol. 16:16643472025. View Article : Google Scholar : PubMed/NCBI

85 

Yao G and Yang Z: Glypican-3 knockdown inhibits the cell growth, stemness, and glycolysis development of hepatocellular carcinoma cells under hypoxic microenvironment through lactylation. Arch Physiol Biochem. 130:546–554. 2024.

86 

Liu Y, Chen J, Ma L, Zhao S, Hui X, Xiong W, Cheng S and Zhang Y: ZMIZ1 lactylation induces tamoxifen resistance in breast cancer through increasing transcriptional activity of Nanog to impact cell stemness and cholesterol uptake. Cell Biol Toxicol. 41:1172025. View Article : Google Scholar : PubMed/NCBI

87 

Deng J, Li Y, Yin L, Liu S, Li Y, Liao W, Mu L, Luo X and Qin J: Histone lactylation enhances GCLC expression and thus promotes chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis. Cell Death Dis. 16:1932025. View Article : Google Scholar : PubMed/NCBI

88 

Zhao Y, Liu W, Deng K, Chen Y, Zhou P, Liu C, Jiang G, Wu J, Zhang Y, Qu H, et al: LncRNA BASP1-AS1 drives PCBP2 K115 lactylation to suppress ferroptosis and confer oxaliplatin resistance in gastric cancer. Free Radic Biol Med. 240:717–734. 2025. View Article : Google Scholar : PubMed/NCBI

89 

Gao M, Wang S, Huang Z, Wang T and Yu Y: H3K18la Facilitates TRA2A-Mediated alternative splicing of STIL, suppressing ferroptosis and cisplatin treatment sensitivity in ovarian cancer. Cancer Res Treat. 58:1428–1448. 2026. View Article : Google Scholar :

90 

Sun C, Li X, Teng Q, Liu X, Song L, Schiöth HB, Wu H, Ma X, Zhang Z, Qi C, et al: Targeting platinum-resistant ovarian cancer by disrupting histone and RAD51 lactylation. Theranostics. 15:3055–3075. 2025. View Article : Google Scholar : PubMed/NCBI

91 

Yue Q, Wang Z, Shen Y, Lan Y, Zhong X, Luo X, Yang T, Zhang M, Zuo B, Zeng T, et al: Histone H3K9 lactylation confers temozolomide resistance in glioblastoma via LUC7L2-Mediated MLH1 intron retention. Adv Sci (Weinh). 11:e23092902024. View Article : Google Scholar : PubMed/NCBI

92 

Dai J, Lu X, Zhang C, Qu T, Li W, Su J, Guo R, Yin D, Wu P, Han L and Zhang E: NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer. Mol Cancer. 24:792025. View Article : Google Scholar : PubMed/NCBI

93 

Li A, Gong Z, Long Y, Li Y, Liu C, Lu X, Li Q, He X, Lu H, Wu K, et al: Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma. Dev Cell. 60:1974–1990.e11. 2025. View Article : Google Scholar : PubMed/NCBI

94 

Lu Y, Zhu J, Zhang Y, Li W, Xiong Y, Fan Y, Wu Y, Zhao J, Shang C, Liang H and Zhang W: Lactylation-Driven IGF2BP3-Mediated serine metabolism reprogramming and RNA m6A-Modification promotes lenvatinib resistance in HCC. Adv Sci (Weinh). 11:e24013992024. View Article : Google Scholar : PubMed/NCBI

95 

Dong R, Fei Y, He Y, Gao P, Zhang B, Zhu M, Wang Z, Wu L, Wu S, Wang X, et al: Lactylation-Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib. Adv Sci (Weinh). 12:e24125592025. View Article : Google Scholar : PubMed/NCBI

96 

Zeng Y, Jiang H, Chen Z, Xu J, Zhang X, Cai W, Zeng X, Ma P, Lin R, Yu H, et al: Histone lactylation promotes multidrug resistance in hepatocellular carcinoma by forming a positive feedback loop with PTEN. Cell Death Dis. 16:592025. View Article : Google Scholar : PubMed/NCBI

97 

Chen HJ, Yu MM, Huang JC, Lan FY, Liao HH, Xu ZH, Yu YJ, Huang YC and Chen F: SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer. Cancer Lett. 597:2170702024. View Article : Google Scholar : PubMed/NCBI

98 

Sun R, Huang Y, He H, Li Q, Wang L, Zhang G, Wei Z, Cao Y, Li J, Wang X, et al: KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/hnRNPA1 lactylation/AR-V7 axis. Mol Cancer. 25:972026. View Article : Google Scholar

99 

Tong H, Jiang Z, Song L, Tan K, Yin X, He C, Huang J, Li X, Jing X, Yun H, et al: Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation. Cell Metab. 38:2472026. View Article : Google Scholar

100 

Liu S, Pan Y, Liu W, Bu X, Shao R, Wang Q, Wu J, Wu C, Hu W, Xu J, et al: Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma. J Immunother Cancer. 13:e0122302025. View Article : Google Scholar : PubMed/NCBI

101 

Chen Q, Yuan H, Bronze MS and Li M: Targeting lactylation and the STAT3/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma. J Clin Invest. 135:e1914222025. View Article : Google Scholar : PubMed/NCBI

102 

Sun K, Zhang X, Shi J, Huang J, Wang S, Li X, Lin H, Zhao D, Ye M, Zhang S, et al: Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. J Clin Invest. 135:e1870242025. View Article : Google Scholar : PubMed/NCBI

103 

Wang R, Li C, Cheng Z, Li M, Shi J, Zhang Z, Jin S and Ma H: H3K9 lactylation in malignant cells facilitates CD8(+) T cell dysfunction and poor immunotherapy response. Cell Rep. 43:1146862024. View Article : Google Scholar

104 

Zhang C, Zhou L, Zhang M, Du Y, Li C, Ren H and Zheng L: H3K18 Lactylation potentiates immune escape of non-small cell lung cancer. Cancer Res. 84:3589–3601. 2024. View Article : Google Scholar : PubMed/NCBI

105 

Chao J, Chen GD, Huang ST, Gu H, Liu YY, Luo Y, Lin Z, Chen ZZ, Li X, Zhang B, et al: High histone H3K18 lactylation level is correlated with poor prognosis in epithelial ovarian cancer. Neoplasma. 71:319–332. 2024. View Article : Google Scholar : PubMed/NCBI

106 

Zhao Y, Xing Z, Zhao Y, Xu H, Liu R, Yang T, Wang Y and Zhu X: Lactylation prognostic signature identifies DHCR7 as a modulator of chemoresistance and immunotherapy efficacy in bladder cancer. Front Immunol. 16:15857272025. View Article : Google Scholar : PubMed/NCBI

107 

Yang X, Li G, Jiang R, Yang Y, Zhu H, Huang L, Li T, Zhou J and Liu Z: Lactylation-related gene signatures for prognosis and treatment response prediction in radiation-resistant non-small cell lung cancer. Discov Oncol. 16:17872025. View Article : Google Scholar : PubMed/NCBI

108 

Hu H, Peng F, Ba Q, Hu W and Lu Y: Integrative machine learning identifies lactylation-related gene signature prognostic for chemotherapeutic efficacy in colorectal carcinoma. Discov Oncol. 17:692025. View Article : Google Scholar : PubMed/NCBI

109 

Chen Y, Wu J, Zhai L, Zhang T, Yin H, Gao H, Zhao F, Wang Z, Yang X, Jin M, et al: Metabolic regulation of homologous recombination repair by MRE11 lactylation. Cell. 187:294–311.e21. 2024. View Article : Google Scholar

110 

Yang Z, Su W, Zhang Q, Niu L, Feng B, Zhang Y, Huang F, He J, Zhou Q, Zhou X, et al: Lactylation of HDAC1 confers resistance to ferroptosis in colorectal cancer. Adv Sci (Weinh). 12:e24088452025. View Article : Google Scholar : PubMed/NCBI

111 

Fu Q, Cat A and Zheng YG: New histone lysine acylation biomarkers and their roles in epigenetic regulation. Curr Protoc. 3:e7462023. View Article : Google Scholar : PubMed/NCBI

112 

Sun L, Zhang Y, Yang B, Sun S, Zhang P, Luo Z, Feng T, Cui Z, Zhu T, Li Y, et al: Lactylation of METTL16 promotes cuproptosis via m(6)A-modification on FDX1 mRNA in gastric cancer. Nat Commun. 14:65232023. View Article : Google Scholar : PubMed/NCBI

113 

Rao K, Zhang X, Luo Y, Xia Q, Jin Y and He J: Lactylation orchestrates ubiquitin-independent degradation of cGAS and promotes tumor growth. Cell Rep. 44:1154412025. View Article : Google Scholar : PubMed/NCBI

114 

Lao Y, Jin Y, Wu S, Fang T, Wang Q, Sun L and Sun B: Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma. Mol Cancer. 23:2832024. View Article : Google Scholar : PubMed/NCBI

115 

Chen S, Li Y, Hu J, Li H, Hu C, Zhao J, Qian H, Bai S, Tang Z and Feng Y: Integrating bulk RNA-seq, scRNA-seq, and spatial transcriptomics data to identify novel post-translational modification-related molecular subtypes and therapeutic responses in hepatocellular carcinoma. Cancer Cell Int. 25:3302025. View Article : Google Scholar : PubMed/NCBI

116 

Krishnamoorthy G, Kaiser P, Abu Abed U, Weiner J III, Moura-Alves P, Brinkmann V and Kaufmann SHE: FX11 limits Mycobacterium tuberculosis growth and potentiates bactericidal activity of isoniazid through host-directed activity. Dis Model Mech. 13:dmm0419542020. View Article : Google Scholar : PubMed/NCBI

117 

Sun T, Liu B, Li Y, Wu J, Cao Y, Yang S, Tan H, Cai L, Zhang S, Qi X, et al: Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation. J Exp Clin Cancer Res. 42:2532023. View Article : Google Scholar : PubMed/NCBI

118 

Ge H, Malsiu F, Gao Y, Losmanova T, Blank F, Ott J, Medová M, Peng RW, Deng H, Dorn P and Marti TM: Inhibition of LDHB suppresses the metastatic potential of lung cancer by reducing mitochondrial GSH catabolism. Cancer Lett. 611:2173532025. View Article : Google Scholar

119 

Lopez E, Karattil R, Nannini F, Weng-Kit Cheung G, Denzler L, Galvez-Cancino F, Quezada S and Pule MA: Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies. J Immunother Cancer. 11:e0062872023. View Article : Google Scholar : PubMed/NCBI

120 

Saulle E, Spinello I, Quaranta MT, Pasquini L, Pelosi E, Iorio E, Castelli G, Chirico M, Pisanu ME, Ottone T, et al: Targeting lactate metabolism by inhibiting MCT1 or MCT4 impairs leukemic cell proliferation, induces two different related death-pathways and increases chemotherapeutic sensitivity of acute myeloid leukemia cells. Front Oncol. 10:6214582021. View Article : Google Scholar : PubMed/NCBI

121 

Bridgewater HE, Bolitho EM, Romero-Canelón I, Sadler PJ and Coverdale JPC: Targeting cancer lactate metabolism with synergistic combinations of synthetic catalysts and monocarboxylate transporter inhibitors. J Biol Inorg Chem. 28:345–353. 2023. View Article : Google Scholar : PubMed/NCBI

122 

Chen ZX, Liu MD, Guo DK, Zou MZ, Wang SB, Cheng H, Zhong Z and Zhang XZ: A MSN-based tumor-targeted nanoplatform to interfere with lactate metabolism to induce tumor cell acidosis for tumor suppression and anti-metastasis. Nanoscale. 12:2966–2972. 2020. View Article : Google Scholar : PubMed/NCBI

123 

Hu M, Zhao Y, Cao Y, Tang Q, Feng Z, Ni J and Zhou X: DRP1 promotes lactate utilization in KRAS-mutant non-small-cell lung cancer cells. Cancer Sci. 111:3588–3599. 2020. View Article : Google Scholar : PubMed/NCBI

124 

Khamoui AV, Tokmina-Roszyk D, Rossiter HB, Fields GB and Visavadiya NP: Hepatic proteome analysis reveals altered mitochondrial metabolism and suppressed acyl-CoA synthetase-1 in colon-26 tumor-induced cachexia. Physiol Genomics. 52:203–216. 2020. View Article : Google Scholar : PubMed/NCBI

125 

Zeng Z, Lan J, Lei S, Yang Y, He Z, Xue Y and Chen T: Simultaneous inhibition of ornithine decarboxylase 1 and pyruvate kinase M2 exerts synergistic effects against hepatocellular carcinoma cells. Onco Targets Ther. 13:11697–11709. 2020. View Article : Google Scholar : PubMed/NCBI

126 

Qin X, Zhang M, Hu X, Du Q, Zhao Z, Jiang Y and Luan Y: Nanoengineering of a newly designed chlorin e6 derivative for amplified photodynamic therapy via regulating lactate metabolism. Nanoscale. 13:11953–11962. 2021. View Article : Google Scholar : PubMed/NCBI

127 

Zhang Y, Li L, Li Y, Fei Y, Xue C, Yao X, Zhao Y, Wang X, Li M and Luo Z: An ROS-activatable nanoassembly remodulates tumor cell metabolism for enhanced ferroptosis therapy. Adv Healthc Mater. 11:e21017022022. View Article : Google Scholar

128 

Zhang F, Gu T, Li J, Zhu Y, Chu M, Zhou Q and Liu J: Emodin regulated lactate metabolism by inhibiting MCT1 to delay non-small cell lung cancer progression. Hum Cell. 38:112024. View Article : Google Scholar : PubMed/NCBI

129 

Xu H, Li L, Wang S, Wang Z, Qu L, Wang C and Xu K: Royal jelly acid suppresses hepatocellular carcinoma tumorigenicity by inhibiting H3 histone lactylation at H3K9la and H3K14la sites. Phytomedicine. 118:1549402023. View Article : Google Scholar : PubMed/NCBI

130 

Yu Y, Huang X, Liang C and Zhang P: Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer. Eur J Pharmacol. 957:1760072023. View Article : Google Scholar : PubMed/NCBI

131 

Li M, Zhu T, Jiang F, Zhang W, Gao Y, Shen M, Yu J and Zheng J: Ginsenoside Rk1 suppresses the epithelial-mesenchymal transition of hepatic stellate cells via PFKFB2-mediated aerobic glycolysis. Chem Biol Interact. 421:1117602025. View Article : Google Scholar : PubMed/NCBI

132 

Kumstel S, Schreiber T, Goldstein L, Stenzel J, Lindner T, Joksch M, Zhang X, Wendt EHU, Schönrogge M, Krause B, et al: Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. PLoS One. 17:e02666012022. View Article : Google Scholar : PubMed/NCBI

133 

Zhang Y, Wu X, Wang K, Tang Y, Lu X, Sun F, Tang H, Chen X and Ning S: Simultaneous reversal of T lymphocytes and cancer cells metabolism via a biomimetic heavy-atom-free photosensitizers-based combination therapies to boost cancer photoimmunotherapy. Adv Sci (Weinh). 12:e24161432025. View Article : Google Scholar : PubMed/NCBI

134 

Deng X, Zhu Y, Dai Z, Liu Q, Song Z, Liu T, Huang Y and Chen H: A Bimetallic Nanomodulator to Reverse Immunosuppression via Sonodynamic-Ferroptosis and Lactate Metabolism Modulation. Small. 20:e24045802024. View Article : Google Scholar : PubMed/NCBI

135 

Li Y, Wei Y, Ma S, Li F, Meng X and Yu S: A dual-transformable MgGa-MOF nanoplatform for HCC therapy via lactate metabolism blockade and immune reactivation. J Nanobiotechnology. 24:4522026. View Article : Google Scholar : PubMed/NCBI

136 

Cheng Z, Huang H, Li M, Liang X, Tan Y and Chen Y: Lactylation-related gene signature effectively predicts prognosis and treatment responsiveness in hepatocellular carcinoma. Pharmaceuticals (Basel). 16:6442023. View Article : Google Scholar : PubMed/NCBI

137 

Xie B, Lin J, Chen X, Zhou X, Zhang Y, Fan M, Xiang J, He N, Hu Z and Wang F: CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer. Mol Cancer. 22:1512023. View Article : Google Scholar : PubMed/NCBI

138 

Wu Q, Li X, Long M, Xie X and Liu Q: Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma. Sci Rep. 13:186422023. View Article : Google Scholar : PubMed/NCBI

139 

Wu X: In-depth discovery of protein lactylation in hepatocellular carcinoma. Proteomics,. 23:e23000032023. View Article : Google Scholar : PubMed/NCBI

140 

Shao C, Tang S, Yu S, Liu C, Zhang Y, Wan T, He Z, Yuan Q, Wu S, Zhang H, et al: Genetic code expansion reveals site-specific lactylation in living cells reshapes protein functions. Nat Commun. 16:2272025. View Article : Google Scholar : PubMed/NCBI

141 

Wang X, Liu X, Xiao R, Fang Y, Zhou F, Gu M, Luo X, Jiang D, Tang Y, You L and Zhao Y: Histone lactylation dynamics: Unlocking the triad of metabolism, epigenetics, and immune regulation in metastatic cascade of pancreatic cancer. Cancer Lett. 598:2171172024. View Article : Google Scholar : PubMed/NCBI

142 

Chen B, Deng Y, Hong Y, Fan L, Zhai X, Hu H, Yin S, Chen Q, Xie X, Ren X, et al: Metabolic recoding of NSUN2-Mediated m(5)C modification promotes the progression of colorectal cancer via the NSUN2/YBX1/m(5)C-ENO1 positive feedback loop. Adv Sci (Weinh). 11:e23098402024. View Article : Google Scholar : PubMed/NCBI

143 

Liu J, Du J, Li Y, Wang F, Song D, Lin J, Li B and Li L: Catalpol induces apoptosis in breast cancer in vitro and in vivo: Involvement of mitochondria apoptosis pathway and post-translational modifications. Toxicol Appl Pharmacol. 454:1162152022. View Article : Google Scholar : PubMed/NCBI

144 

Lai FL and Gao F: Auto-Kla: a novel web server to discriminate lysine lactylation sites using automated machine learning. Brief Bioinform. 24:bbad0702023. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Yang Y, Zhang N, Wang D, Ye D, Zhang Y and Li X: Metabolic‑epigenetic coupling via lysine lactylation drives cancer stemness and multidrug resistance (Review). Int J Oncol 69: 142, 2026.
APA
Yang, Y., Zhang, N., Wang, D., Ye, D., Zhang, Y., & Li, X. (2026). Metabolic‑epigenetic coupling via lysine lactylation drives cancer stemness and multidrug resistance (Review). International Journal of Oncology, 69, 142. https://doi.org/10.3892/ijo.2026.5955
MLA
Yang, Y., Zhang, N., Wang, D., Ye, D., Zhang, Y., Li, X."Metabolic‑epigenetic coupling via lysine lactylation drives cancer stemness and multidrug resistance (Review)". International Journal of Oncology 69.6 (2026): 142.
Chicago
Yang, Y., Zhang, N., Wang, D., Ye, D., Zhang, Y., Li, X."Metabolic‑epigenetic coupling via lysine lactylation drives cancer stemness and multidrug resistance (Review)". International Journal of Oncology 69, no. 6 (2026): 142. https://doi.org/10.3892/ijo.2026.5955
Copy and paste a formatted citation
x
Spandidos Publications style
Yang Y, Zhang N, Wang D, Ye D, Zhang Y and Li X: Metabolic‑epigenetic coupling via lysine lactylation drives cancer stemness and multidrug resistance (Review). Int J Oncol 69: 142, 2026.
APA
Yang, Y., Zhang, N., Wang, D., Ye, D., Zhang, Y., & Li, X. (2026). Metabolic‑epigenetic coupling via lysine lactylation drives cancer stemness and multidrug resistance (Review). International Journal of Oncology, 69, 142. https://doi.org/10.3892/ijo.2026.5955
MLA
Yang, Y., Zhang, N., Wang, D., Ye, D., Zhang, Y., Li, X."Metabolic‑epigenetic coupling via lysine lactylation drives cancer stemness and multidrug resistance (Review)". International Journal of Oncology 69.6 (2026): 142.
Chicago
Yang, Y., Zhang, N., Wang, D., Ye, D., Zhang, Y., Li, X."Metabolic‑epigenetic coupling via lysine lactylation drives cancer stemness and multidrug resistance (Review)". International Journal of Oncology 69, no. 6 (2026): 142. https://doi.org/10.3892/ijo.2026.5955
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team